



PCT/GB 2003 / 005404



INVESTOR IN PEOPLE

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 23 JAN 2004


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed 

Dated 9 January 2004

BEST AVAILABLE COPY

Patents Form 177

THE PATENT OFFICE

11 DEC 2002

**Request for grant of a patent**

(See the notes on the back of this form. You can also  
get an explanatory leaflet from the Patent Office to  
help you fill in this form.)

**The  
Patent  
Office**

177  
12DEC02 E770374-9 D00019  
P01/7700 080-1228957.7

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference

P032668GB: HRG

2. Patent application number

(The Patent Office will fill in this part)

0228957.7

11 DEC 2002

3. Full name, address and postcode of the or of  
each applicant (*underline all surnames*)

INPHARMATICA LIMITED  
60 Charlotte Street  
London  
W1T 2NU

78532 86002

Patents ADP number (*if you know it*)

If the applicant is a corporate body, give the  
country/state of its incorporation

United Kingdom

4. Title of the invention

PROTEIN

5. Name of your agent (*if you have one*)

Carpmaels & Ransford

"Address for service" in the United Kingdom  
to which all correspondence should be sent  
(*including the postcode*)

43 Bloomsbury Square  
London  
WC1A 2RA

Patents ADP number (*if you know it*)

83001

6. If you are declaring priority from one or more  
earlier patent applications, give the country  
and the date of filing of the or of each of these  
earlier applications and (*if you know it*) the or  
each application number

Country

Priority application number  
(*if you know it*)

Date of filing  
(*day / month / year*)

7. If this application is divided or otherwise  
derived from an earlier UK application,  
give the number and the filing date of  
the earlier application

Number of earlier application

Date of filing  
(*day / month / year*)

8. Is a statement of inventorship and of right  
to grant of a patent required in support of  
this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body

Yes

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

Continuation sheets of this form

Description	52
Claim(s)	9
Abstract	
Drawing(s)	7 + 7

- 
10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination  
(*Patents Form 10/77*)

Any other documents  
(please specify)

- 
11. I/We request the grant of a patent on the basis of this application.

Signature

Date

*Carpmaels & Ransford*  
Carpmaels & Ransford

11th December 2002

- 
12. Name and daytime telephone number of person to contact in the United Kingdom

Hugh Goodfellow

020-7242 8692

---

**Warning**

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

**Notes**

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

## **Protein**

This invention relates to a novel protein, termed INTP039, herein identified as a serine protease, in particular, as a member of the trypsin family of proteins and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and  
5 treatment of disease.

All publications, patents and patent applications cited herein are incorporated in full by reference.

### **Background**

The process of drug discovery is presently undergoing a fundamental revolution as the era  
10 of functional genomics comes of age. The term "functional genomics" applies to an approach utilising bioinformatics tools to ascribe function to protein sequences of interest. Such tools are becoming increasingly necessary as the speed of generation of sequence data is rapidly outpacing the ability of research laboratories to assign functions to these protein sequences.

15 As bioinformatics tools increase in potency and in accuracy, these tools are rapidly replacing the conventional techniques of biochemical characterisation. Indeed, the advanced bioinformatics tools used in identifying the present invention are now capable of outputting results in which a high degree of confidence can be placed.

Various institutions and commercial organisations are examining sequence data as they  
20 become available and significant discoveries are being made on an on-going basis. However, there remains a continuing need to identify and characterise further genes and the polypeptides that they encode, as targets for research and for drug discovery.

### **Introduction**

Proteases are enzymes that irreversibly hydrolyse amide bonds in peptides and proteins.  
25 Proteases are widely distributed and are involved in many different biological processes, from activation of proteins and peptides to degradation of proteins. Despite the fact that proteases have been shown to be involved in many different diseases, drugs targeted to proteases are still rare in pharmacy, although inhibitors of angiotensin converting enzyme have been among the most successful antihypertensive drugs for several years. Proteases

have recently received substantial publicity as valuable therapeutic targets following the approval of HIV protease inhibitors.

Proteases can be divided in large Families. The term "Family" is used to describe a group of proteases in which each member shows an evolutionary relationship to at least one other member, either throughout the whole sequence or at least in the part of the sequence responsible for catalytic activity. The name of each Family reflects the catalytic activity type of the proteases in the Family. Thus, serine proteases belong to the S family, threonine proteases belong to the T family, aspartyl proteases belong to the A family, cysteine proteases belong to the C family and metalloproteases belong to the M family.

10 Certain proteases have an unknown mechanism of action and belong to the "U" family.

#### Serine proteases (S family)

The serine proteases are grouped into 7 clans, containing 39 families and over 750 different members from various species. Of these 39 families, only 9 contain members that are expressed in animals. Families with particularly interesting members include the S1 Family and the S26 Family. The S26 Family includes bacterial leader peptidase I, which has been implicated as an important agent in bacterial infection (Paetzl, M., *et al.*, Proteins (1995), (1):122-5; Tschantz, W.R., Methods Enzymol. (1994), 244:285-301).

20 The S1 Family is the largest of these 9 families and the family with by far the greatest number of members of significance to health and disease. This family includes clotting factors such as factors VII, IX, X, XI and XII, proteases of the complement system, plasmin, trypsin, UPA, elastases such as leukocyte elastase, chymase, thrombin, cathepsin G, plasminogen, tryptase, urokinase and many others.

25 The prototypic protease of this family is chymotrypsin. The catalytic activity of the S1 family of proteases is provided by a charge relay system involving an aspartic acid residue that is hydrogen-bonded to a histidine, which itself is hydrogen-bonded to a serine. The sequences in the vicinity of the active site serine and histidine residues are well conserved in this family of proteases.

30 Serine proteases have been shown to play a role in diverse physiological functions, many of which can play a role in disease processes (see Table 1) such as cardiovascular disease (Kohler, H.T., *et al.*, (2000) N. Engl. J. Med. 342(24):1792-801; Hamsten, A., *et al.*, (2000) Thromb. Haemost. 83(3):397-403; Calif, R.M., *et al.*, (2000) Circulation,

101(19):2231-8; Krendel, S., *et al.*, (2000) Ann. Emerg. Med. 35(5):502-5), cancer  
 (Schmidt, M., *et al.*, (1999) Acta Otolaryngol. 119(8):949-53; Raigoso, P., *et al.*, (2000)  
 Int. J. Biol. Markers, 15(1):44-50; Haese, A., *et al.*, (2000) J. Urol. 163(5):1491-7;  
 Hoopera, J.D., *et al.*, (2000) Biochim. Biophys. Acta, 2000, 1492(1):63-71; Wallrapp, C.,  
 5 *et al.*, (2000) Cancer Res. 2000, 60(10):2602-6; Cao, Y., *et al.*, (2000) Int. J. Mol. Med.  
 2000, 5(5):547-51), asthma, chronic obstructive pulmonary disease (COPD), inflammatory  
 diseases (Rice, K.D., *et al.*, (1998) Curr. Pharm. Des., (5):381-96; Nadel, J.A., *et al.*,  
 (1998) Eur. Respir. J., (6):1250-1; Wright, C.D., *et al.*, (1999) Biochem. Pharmacol.,  
 10 58(12):1989-96; Burgess, L.E., *et al.*, (1999) Proc. Natl. Acad. Sci. U. S. A., 96(15):8348-  
 52; Barnes, P.J., *et al.*, (2000) Chest, 117(2 Suppl):10S-4S) and bacterial infections (Al-  
 Hasani, K., *et al.*, (2000) Infect. Immun., 68(5):2457-63; Gaillot, O., *et al.*, (2000) Mol  
 Microbiol. 35(6):1286-94; Lejal, N., *et al.*, (2000) J. Gen. Virol., 81(Pt 4):983-92).

15 Alteration of their activity is a means to alter the disease phenotype and as such  
 identification of novel serine proteases is highly relevant as they may play a role in the  
 diseases identified as well as other disease states. As such, the identification of novel  
 serine proteases is highly relevant for the treatment and diagnosis of disease, particularly  
 those identified in Table 1 below.

**Table 1**

Protease name	Biological function	Associated disease
Thrombin	Converts fibrinogen to fibrin	Cardiovascular
Factor Xa	Converts prothrombin to thrombin in blood coagulation	Cardiovascular
Factor VIIa	Proteolytically activates coagulation factors IX and X	Cardiovascular
chymase	Hydrolyses extracellular matrix proteins and others after release from mast cells	Asthma
tryptase	Hydrolyses extracellular matrix proteins and others after release from mast cells	Asthma
Leukocyte elastase	Proteolyses bacterial extracellular matrix components	Emphysema, cystic fibrosis, adult respiratory distress syndrome, rheumatoid arthritis

Thrombin	Clotting of blood by processing of fibrinogen	Cardiovascular
Complement C1r and C1s	Activation of complement	Xenotransplantation, sepsis
Urokinase	Activates plasminogen to plasmin in fibrinolysis	Cardiovascular, oncology
Bacterial leader peptidase I	Hydrolysis of signal peptides of secreted proteins other than lipoproteins	Bacterial infections

Increasing knowledge of these proteins is therefore of extreme importance in increasing the understanding of the underlying pathways that lead to the disease states and associated disease states mentioned above, and in developing more effective gene and/or drug therapies to treat these disorders.

## 5 THE INVENTION

The invention is based on the discovery that the INTP039 polypeptide is a member of the trypsin family of proteins.

In one embodiment of the first aspect of the invention, there is provided a polypeptide which:

- 10 (i) comprises the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and/or SEQ ID NO:26;
- (ii) is a fragment thereof which functions as a serine protease which is a member of the trypsin family of proteins, or has an antigenic determinant in common with the polypeptides of (i); or
- 15 (iii) is a functional equivalent of (i) or (ii).

Preferably, the polypeptide according to this first aspect of the invention:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:22 and/or SEQ ID NO:26;
- (ii) is a fragment thereof which functions as a serine protease which is a member of the trypsin family of proteins, or has an antigenic determinant in common with the

polypeptides of (i); or

- (iii) is a functional equivalent of (i) or (ii).

According to a second embodiment of this first aspect of the invention, there is provided a polypeptide which:

- 5 (i) consists of the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and/or SEQ ID NO:26;
- 10 (ii) is a fragment thereof which functions as a serine protease which is a member of the trypsin family of proteins, or having an antigenic determinant in common with the polypeptides of (i); or
- (iii) is a functional equivalent of (i) or (ii).

The polypeptide having the sequence recited in SEQ ID NO:2 is referred to hereafter as "INTP039 exon 1 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:4 is referred to hereafter as "INTP039 exon 2 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:6 is referred to hereafter as "INTP039 exon 3 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:8 is referred to hereafter as "INTP039 exon 4 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:10 is referred to hereafter as "INTP039 exon 5 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:12 is referred to hereafter as "INTP039 exon 6 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:14 is referred to hereafter as "INTP039 exon 7 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:16 is referred to hereafter as "INTP039 exon 8 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:18 is referred to hereafter as "INTP039 exon 9 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:20 is referred to hereafter as "INTP039 exon 10 polypeptide". The polypeptide having the sequence recited in SEQ ID NO:22 is referred to hereafter as the "INTP039 polypeptide".

Although the Applicant does not wish to be bound by this theory, it is postulated that the first 23 amino acids of the INTP039 polypeptide form a signal peptide.

The INTP039 exon 2 and full length INTP039 polypeptide sequences without this

postulated signal sequence are recited in SEQ ID NO:24 and SEQ ID NO:26 respectively.

The polypeptide having the sequence recited in SEQ ID NO:24 is referred to hereafter as "the INTP039 exon 2 mature polypeptide". The polypeptide having the sequence recited in SEQ ID NO:26 is referred to hereafter as "the INTP039 mature polypeptide".

- 5 The term "INTP039 polypeptides" as used herein includes polypeptides comprising the INTP039 exon 1 polypeptide, the INTP039 exon 2 polypeptide, the INTP039 exon 3 polypeptide, the INTP039 exon 4 polypeptide, the INTP039 exon 5 polypeptide, the INTP039 exon 6 polypeptide, the INTP039 exon 7 polypeptide, the INTP039 exon 8 polypeptide, the INTP039 exon 9 polypeptide, the INTP039 exon 10 polypeptide, the  
10 INTP039 polypeptide, the INTP039 exon 2 mature polypeptide and the INTP039 mature polypeptide.

By "functions as a member of the trypsin family of proteins" we refer to polypeptides that comprise amino acid sequence or structural features that can be identified as conserved features within the polypeptides of the trypsin family, such that the polypeptide's  
15 interaction with ligand is not substantially affected detrimentally in comparison to the function of the full length wild type polypeptide. In particular, we refer to the presence of cysteine residues in specific positions within the polypeptide that allow the formation of intra-domain disulphide bonds. Protease activity can be detected by various assays including the ProCheck™ Universal Protease Assay (Serologicals Corporation). This is  
20 able to detect enzyme levels as low as  $1 \times 10^{-4}$  Units.

In a second aspect, the invention provides a purified nucleic acid molecule which encodes a polypeptide of the first aspect of the invention.

Preferably, the purified nucleic acid molecule comprises the nucleic acid sequence as recited in SEQ ID NO:1 (encoding the INTP039 exon 1 polypeptide), SEQ ID NO:3  
25 (encoding the INTP039 exon 2 polypeptide), SEQ ID NO:5 (encoding the INTP039 exon 3 polypeptide), SEQ ID NO:7 (encoding the INTP039 exon 4 polypeptide), SEQ ID NO:9 (encoding the INTP039 exon 5 polypeptide), SEQ ID NO:11 (encoding the INTP039 exon 6 polypeptide), SEQ ID NO:13 (encoding the INTP039 exon 7 polypeptide), SEQ ID NO:15 (encoding the INTP039 exon 8 polypeptide), SEQ ID NO:17 (encoding the  
30 INTP039 exon 9 polypeptide), SEQ ID NO:19 (encoding the INTP039 exon 10 polypeptide), SEQ ID NO:21 (encoding the INTP039 polypeptide), SEQ ID NO:23 (encoding the INTP039 exon 2 mature polypeptide) and/or SEQ ID NO:25 (encoding the

INTP039 mature polypeptide) or is a redundant equivalent or fragment of any one of these sequences.

The invention further provides that the purified nucleic acid molecule consists of the nucleic acid sequence as recited in SEQ ID NO:1 (encoding the INTP039 exon 1 polypeptide), SEQ ID NO:3 (encoding the INTP039 exon 2 polypeptide), SEQ ID NO:5 (encoding the INTP039 exon 3 polypeptide), SEQ ID NO:7 (encoding the INTP039 exon 4 polypeptide), SEQ ID NO:9 (encoding the INTP039 exon 5 polypeptide), SEQ ID NO:11 (encoding the INTP039 exon 6 polypeptide), SEQ ID NO:13 (encoding the INTP039 exon 7 polypeptide), SEQ ID NO:15 (encoding the INTP039 exon 8 polypeptide), SEQ ID NO:17 (encoding the INTP039 exon 9 polypeptide), SEQ ID NO:19 (encoding the INTP039 exon 10 polypeptide), SEQ ID NO:21 (encoding the INTP039 polypeptide), SEQ ID NO:23 (encoding the INTP039 exon 2 mature polypeptide) and/or SEQ ID NO:25 (encoding the INTP039 mature polypeptide) or is a redundant equivalent or fragment of any one of these sequences.

15 In a third aspect, the invention provides a purified nucleic acid molecule which hybridizes under high stringency conditions with a nucleic acid molecule of the second aspect of the invention.

In a fourth aspect, the invention provides a vector, such as an expression vector, that contains a nucleic acid molecule of the second or third aspect of the invention.

20 In a fifth aspect, the invention provides a host cell transformed with a vector of the fourth aspect of the invention.

In a sixth aspect, the invention provides a ligand which binds specifically to protein members of the trypsin family of the first aspect of the invention.

25 In a seventh aspect, the invention provides a compound that is effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention.

A compound of the seventh aspect of the invention may either increase (agonise) or decrease (antagonise) the level of expression of the gene or the activity of the polypeptide.

30 Importantly, the identification of the function of the INTP039 polypeptides allows for the design of screening methods capable of identifying compounds that are effective in the treatment and/or diagnosis of disease. Ligands and compounds according to the sixth and

seventh aspects of the invention may be identified using such methods. These methods are included as aspects of the present invention.

In an eighth aspect, the invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention; or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, for use in therapy or diagnosis of diseases in which members of the trypsin family are implicated. Such diseases may include cell proliferative disorders and/or differentiative disorders, such as carcinoma, sarcoma, solid tumours including prostate, breast, lung, testis, ovary, head and neck, brain or bone tumour, metastatic disorders or hematopoietic neoplastic disorders; disorders of bone metabolism, such as osteoporosis, osteodystrophy, osteomalacia, rickets, osteitis fibrosa cystica, renal osteodystrophy, osteosclerosis, osteopenia, fibrogenesis-imperfecta ossium, secondary hyperparathyroidism, hypoparathyroidism, hyperparathyroidism; periodontal disease, immune/autoimmune disorders such as, arthritis, multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus erythematosus, autoimmune thyroiditis, dermatitis, psoriasis, Sjogren's Syndrome, Crohn's disease, ulcer, iritis, conjunctivitis, ulcerative colitis, asthma, scleroderma, autoimmune uveitis, allergic encephalomyelitis, hearing loss, aplastic anemia, anemia, idiopathic thrombocytopenia, polychondritis, Graves' disease, graft-versus-host disease, allergy; hematopoietic disorders; cardiovascular disorders such as hypertension, atherosclerosis, congestive heart failure, coronary artery disease, arrhythmias, cardiomyopathies, artherosclerosis, hypertensive vascular disease, Raynaud disease, aneurysms, varicose veins, thrombophlebitis, phlebothrombosis, tumors, hemangioma, lymphangioma, glomus tumor (glomangioma), Kaposi sarcoma, angiosarcoma, hemangiopericytoma; blood clotting disorders, such as hemorrhagic diatheses, nonthrombocytopenic purpuras, thrombocytopenia, idiopathic thrombocytopenic purpura, HIV-associated thrombocytopenia, thrombotic microangiopathies, hemorrhagic diatheses, lymphomas, Hodgkin disease; liver disorders such as, cirrhosis, hepatocellular necrosis, liver fibrosis, Al-antitrypsin deficiency, hemochromatosis copper storage diseases and liver damage (especially drug or alcohol induced); bacterial, fungal or viral infection; pain or metabolic disorders, such as obesity, anorexia nervosa, cachexia, lipid disorders, and diabetes; AIDS and other pathological conditions.

These molecules may also be used in the manufacture of a medicament for the treatment of such diseases.

In a ninth aspect, the invention provides a method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide of the first aspect of the invention or the activity of a polypeptide of the first aspect of the invention in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease. Such a method will preferably be carried out *in vitro*. Similar methods may be used for monitoring the therapeutic treatment of disease in a patient, wherein altering the level of expression or activity of a polypeptide or nucleic acid molecule over the period of time towards a control level is indicative of regression of disease.

A preferred method for detecting polypeptides of the first aspect of the invention comprises the steps of: (a) contacting a ligand, such as an antibody, of the sixth aspect of the invention with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.

A number of different such methods according to the ninth aspect of the invention exist, as the skilled reader will be aware, such as methods of nucleic acid hybridization with short probes, point mutation analysis, polymerase chain reaction (PCR) amplification and methods using antibodies to detect aberrant protein levels. Similar methods may be used on a short or long term basis to allow therapeutic treatment of a disease to be monitored in a patient. The invention also provides kits that are useful in these methods for diagnosing disease.

In a tenth aspect, the invention provides for the use of a polypeptide of the first aspect of the invention as a serine protease, particularly as a member of the trypsin family. Suitable uses of the polypeptides of the invention as trypsin proteins include use as a regulator of cellular growth, metabolism or differentiation, use as part of a receptor/ligand pair and use as a diagnostic marker for a physiological or pathological condition selected from the list given above.

In an eleventh aspect, the invention provides a pharmaceutical composition comprising a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a

compound of the seventh aspect of the invention, in conjunction with a pharmaceutically-acceptable carrier.

In a twelfth aspect, the present invention provides a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention, for use in the manufacture of a medicament for the diagnosis or treatment of a disease.

In a thirteenth aspect, the invention provides a method of treating a disease in a patient comprising administering to the patient a polypeptide of the first aspect of the invention, or a nucleic acid molecule of the second or third aspect of the invention, or a vector of the fourth aspect of the invention, or a host cell of the fifth aspect of the invention, or a ligand of the sixth aspect of the invention, or a compound of the seventh aspect of the invention.

For diseases in which the expression of a natural gene encoding a polypeptide of the first aspect of the invention, or in which the activity of a polypeptide of the first aspect of the invention, is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, ligand or compound administered to the patient should be an agonist. Conversely, for diseases in which the expression of the natural gene or activity of the polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, ligand or compound administered to the patient should be an antagonist. Examples of such antagonists include antisense nucleic acid molecules, ribozymes and ligands, such as antibodies.

In a fourteenth aspect, the invention provides transgenic or knockout non-human animals that have been transformed to express higher, lower or absent levels of a polypeptide of the first aspect of the invention. Such transgenic animals are very useful models for the study of disease and may also be used in screening regimes for the identification of compounds that are effective in the treatment or diagnosis of such a disease.

A summary of standard techniques and procedures which may be employed in order to utilise the invention is given below. It will be understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors and reagents described. It is also to be understood that the terminology used herein is for the purpose of describing

particular embodiments only and it is not intended that this terminology should limit the scope of the present invention. The extent of the invention is limited only by the terms of the appended claims.

Standard abbreviations for nucleotides and amino acids are used in this specification.

- 5 The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA technology and immunology, which are within the skill of those working in the art.

Such techniques are explained fully in the literature. Examples of particularly suitable texts for consultation include the following: Sambrook Molecular Cloning; A Laboratory Manual, Second Edition (1989); DNA Cloning, Volumes I and II (D.N Glover ed. 1985);  
10 Oligonucleotide Synthesis (M.J. Gait ed. 1984); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds. 1984); Transcription and Translation (B.D. Hames & S.J. Higgins eds. 1984); Animal Cell Culture (R.I. Freshney ed. 1986); Immobilized Cells and Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide to Molecular Cloning (1984); the Methods  
15 in Enzymology series (Academic Press, Inc.), especially volumes 154 & 155; Gene Transfer Vectors for Mammalian Cells (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory); Immunochemical Methods in Cell and Molecular Biology (Mayer and Walker, eds. 1987, Academic Press, London); Scopes, (1987) Protein Purification: Principles and Practice, Second Edition (Springer Verlag, N.Y.); and Handbook of  
20 Experimental Immunology, Volumes I-IV (D.M. Weir and C. C. Blackwell eds. 1986).

As used herein, the term "polypeptide" includes any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e. peptide isosteres. This term refers both to short chains (peptides and oligopeptides) and to longer chains (proteins).

- 25 The polypeptide of the present invention may be in the form of a mature protein or may be a pre-, pro- or prepro- protein that can be activated by cleavage of the pre-, pro- or prepro- portion to produce an active mature polypeptide. In such polypeptides, the pre-, pro- or prepro- sequence may be a leader or secretory sequence or may be a sequence that is employed for purification of the mature polypeptide sequence.  
30 The polypeptide of the first aspect of the invention may form part of a fusion protein. For example, it is often advantageous to include one or more additional amino acid sequences

which may contain secretory or leader sequences, pro-sequences, sequences which aid in purification, or sequences that confer higher protein stability, for example during recombinant production. Alternatively or additionally, the mature polypeptide may be fused with another compound, such as a compound to increase the half-life of the  
5 polypeptide (for example, polyethylene glycol).

- Polypeptides may contain amino acids other than the 20 gene-encoded amino acids, modified either by natural processes, such as by post-translational processing or by chemical modification techniques which are well known in the art. Among the known modifications which may commonly be present in polypeptides of the present invention  
10 are glycosylation, lipid attachment, sulphation, gamma-carboxylation, for instance of glutamic acid residues, hydroxylation and ADP-ribosylation. Other potential modifications include acetylation, acylation, amidation, covalent attachment of flavin, covalent attachment of a haeme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid derivative, covalent attachment of  
15 phosphatidylinositol, cross-linking, cyclization, disulphide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, GPI anchor formation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.  
20 Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl terminus in a polypeptide, or both, by a covalent modification is common in naturally-occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention.  
25 The modifications that occur in a polypeptide often will be a function of how the polypeptide is made. For polypeptides that are made recombinantly, the nature and extent of the modifications in large part will be determined by the post-translational modification capacity of the particular host cell and the modification signals that are present in the amino acid sequence of the polypeptide in question. For instance, glycosylation patterns  
30 vary between different types of host cell.

The polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally-occurring polypeptides (for example purified from

cell culture), recombinantly-produced polypeptides (including fusion proteins), synthetically-produced polypeptides or polypeptides that are produced by a combination of these methods.

The functionally-equivalent polypeptides of the first aspect of the invention may be 5 polypeptides that are homologous to the INTP039 polypeptides. Two polypeptides are said to be "homologous", as the term is used herein, if the sequence of one of the polypeptides has a high enough degree of identity or similarity to the sequence of the other polypeptide. "Identity" indicates that at any particular position in the aligned sequences, the amino acid residue is identical between the sequences. "Similarity" indicates that, at any particular 10 position in the aligned sequences, the amino acid residue is of a similar type between the sequences. Degrees of identity and similarity can be readily calculated (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing. Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A.M., and Griffin, H.G., 15 eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991).

Homologous polypeptides therefore include natural biological variants (for example, allelic variants or geographical variations within the species from which the polypeptides 20 are derived) and mutants (such as mutants containing amino acid substitutions, insertions or deletions) of the INTP039 polypeptides. Such mutants may include polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code. 25 Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; among the basic residues Lys and Arg; or among the aromatic residues Phe and Tyr. Particularly preferred are variants in which several, i.e. between 5 and 10, 1 and 5, 1 and 3, 1 and 2 or just 1 amino acids are substituted, deleted or added in any combination. Especially preferred are silent 30 substitutions, additions and deletions, which do not alter the properties and activities of the protein. Also especially preferred in this regard are conservative substitutions. Such mutants also include polypeptides in which one or more of the amino acid residues includes a substituent group.

Typically, greater than 30% identity between two polypeptides is considered to be an indication of functional equivalence. Preferably, functionally equivalent polypeptides of the first aspect of the invention have a degree of sequence identity with the INTP039 polypeptide, or with active fragments thereof, of greater than 80%. More preferred 5 polypeptides have degrees of identity of greater than 85%, 90%, 95%, 98% or 99%, respectively.

The functionally-equivalent polypeptides of the first aspect of the invention may also be polypeptides which have been identified using one or more techniques of structural alignment. For example, the Inpharmatica Genome Threader technology that forms one 10 aspect of the search tools used to generate the Biopendium™ search database may be used (see PCT application WO 01/69507) to identify polypeptides of presently-unknown function which, while having low sequence identity as compared to the INTP039 polypeptides, are predicted to be members of the trypsin family, by virtue of sharing significant structural homology with the INTP039 polypeptide sequence. By "significant 15 structural homology" is meant that the Inpharmatica Genome Threader predicts two proteins to share structural homology with a certainty of 10% and above.

The polypeptides of the first aspect of the invention also include fragments of the INTP039 polypeptides and fragments of the functional equivalents of the INTP039 polypeptides, provided that those fragments are members of the trypsin family or have an antigenic 20 determinant in common with the INTP039 polypeptides.

As used herein, the term "fragment" refers to a polypeptide having an amino acid sequence that is the same as part, but not all, of the amino acid sequence of the INTP039 polypeptide or one of their functional equivalents. The fragments should comprise at least n consecutive amino acids from the sequence and, depending on the particular sequence, n 25 preferably is 7 or more (for example, 8, 10, 12, 14, 16, 18, 20 or more). Small fragments may form an antigenic determinant.

Fragments of the full length INTP039 polypeptides may consist of combinations of 2, 3, 4, 5, 6, 7, 8, 9 or 10 of neighbouring exon sequences in the INTP039 polypeptide sequences, respectively. For example, such combinations include exons 1 and 2, 2 and 3 or 1, 2 and 3. 30 Such fragments are included in the present invention.

Such fragments may be "free-standing", i.e. not part of or fused to other amino acids or polypeptides, or they may be comprised within a larger polypeptide of which they form a

part or region. When comprised within a larger polypeptide, the fragment of the invention most preferably forms a single continuous region. For instance, certain preferred embodiments relate to a fragment having a pre- and/or pro- polypeptide region fused to the amino terminus of the fragment and/or an additional region fused to the carboxyl terminus 5 of the fragment. However, several fragments may be comprised within a single larger polypeptide.

The polypeptides of the present invention or their immunogenic fragments (comprising at least one antigenic determinant) can be used to generate ligands, such as polyclonal or monoclonal antibodies, that are immunospecific for the polypeptides. Such antibodies may 10 be employed to isolate or to identify clones expressing the polypeptides of the invention or to purify the polypeptides by affinity chromatography. The antibodies may also be employed as diagnostic or therapeutic aids, amongst other applications, as will be apparent to the skilled reader.

The term "immunospecific" means that the antibodies have substantially greater affinity 15 for the polypeptides of the invention than their affinity for other related polypeptides in the prior art. As used herein, the term "antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')<sub>2</sub> and Fv, which are capable of binding to the antigenic determinant in question. Such antibodies thus bind to the polypeptides of the first aspect of the invention.

If polyclonal antibodies are desired, a selected mammal, such as a mouse, rabbit, goat or horse, may be immunised with a polypeptide of the first aspect of the invention. The polypeptide used to immunise the animal can be derived by recombinant DNA technology or can be synthesized chemically. If desired, the polypeptide can be conjugated to a carrier protein. Commonly used carriers to which the polypeptides may be chemically coupled 20 include bovine serum albumin, thyroglobulin and keyhole limpet haemocyanin. The coupled polypeptide is then used to immunise the animal. Serum from the immunised animal is collected and treated according to known procedures, for example by immunoaffinity chromatography.

Monoclonal antibodies to the polypeptides of the first aspect of the invention can also be 30 readily produced by one skilled in the art. The general methodology for making monoclonal antibodies using hybridoma technology is well known (see, for example, Kohler, G. and Milstein, C., Nature 256: 495-497 (1975); Kozbor *et al.*, Immunology

Today 4: 72 (1983); Cole *et al.*, 77-96 in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc. (1985).

Panels of monoclonal antibodies produced against the polypeptides of the first aspect of the invention can be screened for various properties, i.e., for isotype, epitope, affinity, etc.

- 5 Monoclonal antibodies are particularly useful in purification of the individual polypeptides against which they are directed. Alternatively, genes encoding the monoclonal antibodies of interest may be isolated from hybridomas, for instance by PCR techniques known in the art, and cloned and expressed in appropriate vectors.

Chimeric antibodies, in which non-human variable regions are joined or fused to human constant regions (see, for example, Liu *et al.*, Proc. Natl. Acad. Sci. USA, 84, 3439 (1987)), may also be of use.

- The antibody may be modified to make it less immunogenic in an individual, for example by humanisation (see Jones *et al.*, Nature, 321, 522 (1986); Verhoeyen *et al.*, Science, 239, 1534 (1988); Kabat *et al.*, J. Immunol., 147, 1709 (1991); Queen *et al.*, Proc. Natl Acad. Sci. USA, 86, 10029 (1989); Gorman *et al.*, Proc. Natl Acad. Sci. USA, 88, 34181 (1991); and Hodgson *et al.*, Bio/Technology, 9, 421 (1991)). The term "humanised antibody", as used herein, refers to antibody molecules in which the CDR amino acids and selected other amino acids in the variable domains of the heavy and/or light chains of a non-human donor antibody have been substituted in place of the equivalent amino acids in a human antibody.
- 20 The humanised antibody thus closely resembles a human antibody but has the binding ability of the donor antibody.

In a further alternative, the antibody may be a "bispecific" antibody, that is an antibody having two different antigen binding domains, each domain being directed against a different epitope.

- 25 Phage display technology may be utilised to select genes which encode antibodies with binding activities towards the polypeptides of the invention either from repertoires of PCR amplified V-genes of lymphocytes from humans screened for possessing the relevant antibodies, or from naive libraries (McCafferty, J. *et al.*, (1990), Nature 348, 552-554; Marks, J. *et al.*, (1992) Biotechnology 10, 779-783). The affinity of these antibodies can  
30 also be improved by chain shuffling (Clackson, T. *et al.*, (1991) Nature 352, 624-628).

Antibodies generated by the above techniques, whether polyclonal or monoclonal, have

additional utility in that they may be employed as reagents in immunoassays, radioimmunoassays (RIA) or enzyme-linked immunosorbent assays (ELISA). In these applications, the antibodies can be labelled with an analytically-detectable reagent such as a radioisotope, a fluorescent molecule or an enzyme.

- 5 Preferred nucleic acid molecules of the second and third aspects of the invention are those which encode a polypeptide sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26 and functionally equivalent polypeptides. These nucleic acid molecules may be used in the  
10 methods and applications described herein. The nucleic acid molecules of the invention preferably comprise at least n consecutive nucleotides from the sequences disclosed herein where, depending on the particular sequence, n is 10 or more (for example, 12, 14, 15, 18, 20, 25, 30, 35, 40 or more).

The nucleic acid molecules of the invention also include sequences that are complementary  
15 to nucleic acid molecules described above (for example, for antisense or probing purposes).

Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance cDNA, synthetic DNA or genomic DNA. Such nucleic acid molecules may be obtained by cloning, by chemical synthetic  
20 techniques or by a combination thereof. The nucleic acid molecules can be prepared, for example, by chemical synthesis using techniques such as solid phase phosphoramidite chemical synthesis, from genomic or cDNA libraries or by separation from an organism. RNA molecules may generally be generated by the *in vitro* or *in vivo* transcription of DNA sequences.

- 25 The nucleic acid molecules may be double-stranded or single-stranded. Single-stranded DNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

The term "nucleic acid molecule" also includes analogues of DNA and RNA, such as those containing modified backbones, and peptide nucleic acids (PNA). The term "PNA", as  
30 used herein, refers to an antisense molecule or an anti-gene agent which comprises an oligonucleotide of at least five nucleotides in length linked to a peptide backbone of amino acid residues, which preferably ends in lysine. The terminal lysine confers solubility to the

composition. PNAs may be pegylated to extend their lifespan in a cell, where they preferentially bind complementary single stranded DNA and RNA and stop transcript elongation (Nielsen, P.E. *et al.* (1993) Anticancer Drug Des. 8:53-63).

A nucleic acid molecule which encodes a polypeptide of this invention may be identical to  
5 the coding sequence of one or more of the nucleic acid molecules disclosed herein.

These molecules also may have a different sequence which, as a result of the degeneracy  
of the genetic code, encodes a polypeptide SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6,  
SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID  
NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 or SEQ ID NO:26. Such nucleic  
10 acid molecules may include, but are not limited to, the coding sequence for the mature  
polypeptide by itself; the coding sequence for the mature polypeptide and additional  
coding sequences, such as those encoding a leader or secretory sequence, such as a pro-,  
pre- or prepro- polypeptide sequence; the coding sequence of the mature polypeptide, with  
or without the aforementioned additional coding sequences, together with further  
15 additional, non-coding sequences, including non-coding 5' and 3' sequences, such as the  
transcribed, non-translated sequences that play a role in transcription (including  
termination signals), ribosome binding and mRNA stability. The nucleic acid molecules  
may also include additional sequences which encode additional amino acids, such as those  
which provide additional functionalities.

20 The nucleic acid molecules of the second and third aspects of the invention may also  
encode the fragments or the functional equivalents of the polypeptides and fragments of  
the first aspect of the invention. Such a nucleic acid molecule may be a naturally-occurring  
variant such as a naturally-occurring allelic variant, or the molecule may be a variant that  
is not known to occur naturally. Such non-naturally occurring variants of the nucleic acid  
25 molecule may be made by mutagenesis techniques, including those applied to nucleic acid  
molecules, cells or organisms.

Among variants in this regard are variants that differ from the aforementioned nucleic acid  
molecules by nucleotide substitutions, deletions or insertions. The substitutions, deletions  
or insertions may involve one or more nucleotides. The variants may be altered in coding  
30 or non-coding regions or both. Alterations in the coding regions may produce conservative  
or non-conservative amino acid substitutions, deletions or insertions.

The nucleic acid molecules of the invention can also be engineered, using methods

generally known in the art, for a variety of reasons, including modifying the cloning, processing, and/or expression of the gene product (the polypeptide). DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides are included as techniques which may be used to engineer the nucleotide sequences. Site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations and so forth.

Nucleic acid molecules which encode a polypeptide of the first aspect of the invention may be ligated to a heterologous sequence so that the combined nucleic acid molecule encodes a fusion protein. Such combined nucleic acid molecules are included within the second or third aspects of the invention. For example, to screen peptide libraries for inhibitors of the activity of the polypeptide, it may be useful to express, using such a combined nucleic acid molecule, a fusion protein that can be recognised by a commercially-available antibody. A fusion protein may also be engineered to contain a cleavage site located between the sequence of the polypeptide of the invention and the sequence of a heterologous protein so that the polypeptide may be cleaved and purified away from the heterologous protein.

The nucleic acid molecules of the invention also include antisense molecules that are partially complementary to nucleic acid molecules encoding polypeptides of the present invention and that therefore hybridize to the encoding nucleic acid molecules (hybridization). Such antisense molecules, such as oligonucleotides, can be designed to recognise, specifically bind to and prevent transcription of a target nucleic acid encoding a polypeptide of the invention, as will be known by those of ordinary skill in the art (see, for example, Cohen, J.S., Trends in Pharm. Sci., 10, 435 (1989), Okano, J. Neurochem. 56, 560 (1991); O'Connor, J. Neurochem 56, 560 (1991); Lee *et al.*, Nucleic Acids Res 6, 3073 (1979); Cooney *et al.*, Science 241, 456 (1988); Dervan *et al.*, Science 251, 1360 (1991)).

The term "hybridization" as used here refers to the association of two nucleic acid molecules with one another by hydrogen bonding. Typically, one molecule will be fixed to a solid support and the other will be free in solution. Then, the two molecules may be placed in contact with one another under conditions that favour hydrogen bonding. Factors that affect this bonding include: the type and volume of solvent; reaction temperature; time of hybridization; agitation; agents to block the non-specific attachment of the liquid phase molecule to the solid support (Denhardt's reagent or BLOTO); the concentration of the

molecules; use of compounds to increase the rate of association of molecules (dextran sulphate or polyethylene glycol); and the stringency of the washing conditions following hybridization (see Sambrook *et al.* [*supra*]).

The inhibition of hybridization of a completely complementary molecule to a target  
5 molecule may be examined using a hybridization assay, as known in the art (see, for example, Sambrook *et al.* [*supra*]). A substantially homologous molecule will then compete for and inhibit the binding of a completely homologous molecule to the target molecule under various conditions of stringency, as taught in Wahl, G.M. and S.L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol.  
10 152:507-511).

"Stringency" refers to conditions in a hybridization reaction that favour the association of very similar molecules over association of molecules that differ. High stringency hybridisation conditions are defined as overnight incubation at 42°C in a solution comprising 50% formamide, 5XSSC (150mM NaCl, 15mM trisodium citrate), 50mM  
15 sodium phosphate (pH7.6), 5x Denhardts solution, 10% dextran sulphate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1X SSC at approximately 65°C. Low stringency conditions involve the hybridisation reaction being carried out at 35°C (see Sambrook *et al.* [*supra*]). Preferably, the conditions used for hybridization are those of high stringency.

20 Preferred embodiments of this aspect of the invention are nucleic acid molecules that are at least 70% identical over their entire length to a nucleic acid molecule encoding the INTP039 polypeptides and nucleic acid molecules that are substantially complementary to such nucleic acid molecules. Preferably, a nucleic acid molecule according to this aspect of the invention comprises a region that is at least 80% identical over its entire length to such  
25 coding sequences, or is a nucleic acid molecule that is complementary thereto. In this regard, nucleic acid molecules at least 90%, preferably at least 95%, more preferably at least 98%, 99% or more identical over their entire length to the same are particularly preferred. Preferred embodiments in this respect are nucleic acid molecules that encode polypeptides which retain substantially the same biological function or activity as the  
30 INTP039 polypeptides.

The invention also provides a process for detecting a nucleic acid molecule of the invention, comprising the steps of: (a) contacting a nucleic probe according to the

invention with a biological sample under hybridizing conditions to form duplexes; and (b) detecting any such duplexes that are formed.

As discussed additionally below in connection with assays that may be utilised according to the invention, a nucleic acid molecule as described above may be used as a 5. hybridization probe for RNA, cDNA or genomic DNA, in order to isolate full-length cDNAs and genomic clones encoding the INTP039 polypeptides and to isolate cDNA and genomic clones of homologous or orthologous genes that have a high sequence similarity to the gene encoding this polypeptide.

In this regard, the following techniques, among others known in the art, may be utilised 10 and are discussed below for purposes of illustration. Methods for DNA sequencing and analysis are well known and are generally available in the art and may, indeed, be used to practice many of the embodiments of the invention discussed herein. Such methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase (US Biochemical Corp, Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7. 15 polymerase (Amersham, Chicago, IL), or combinations of polymerases and proof-reading exonucleases such as those found in the ELONGASE Amplification System marketed by Gibco/BRL (Gaithersburg, MD). Preferably, the sequencing process may be automated using machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), the Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI Catalyst and 373. 20 and 377 DNA Sequencers (Perkin Elmer).

One method for isolating a nucleic acid molecule encoding a polypeptide with an equivalent function to that of the INTP039 polypeptide is to probe a genomic or cDNA library with a natural or artificially-designed probe using standard procedures that are recognised in the art (see, for example, "Current Protocols in Molecular Biology", Ausubel 25 et al. (eds). Greene Publishing Association and John Wiley Interscience, New York, 1989,1992). Probes comprising at least 15, preferably at least 30, and more preferably at least 50, contiguous bases that correspond to, or are complementary to, nucleic acid sequences from the appropriate encoding gene (SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ 30 ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23 and SEQ ID NO:25), are particularly useful probes. Such probes may be labelled with an analytically-detectable reagent to facilitate their identification. Useful reagents include, but are not limited to,

radioisotopes, fluorescent dyes and enzymes that are capable of catalysing the formation of a detectable product. Using these probes, the ordinarily skilled artisan will be capable of isolating complementary copies of genomic DNA, cDNA or RNA polynucleotides encoding proteins of interest from human, mammalian or other animal sources and 5 screening such sources for related sequences, for example, for additional members of the family, type and/or subtype.

In many cases, isolated cDNA sequences will be incomplete, in that the region encoding the polypeptide will be cut short, normally at the 5' end. Several methods are available to obtain full length cDNAs, or to extend short cDNAs. Such sequences may be extended 10 utilising a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed is based on the method of Rapid Amplification of cDNA Ends (RACE; see, for example, Frohman *et al.*, PNAS USA 85, 8998-9002, 1988). Recent modifications of this technique, exemplified by the Marathon<sup>TM</sup> technology (Clontech 15 Laboratories Inc.), for example, have significantly simplified the search for longer cDNAs. A slightly different technique, termed "restriction-site" PCR, uses universal primers to retrieve unknown nucleic acid sequence adjacent a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). Inverse PCR may also be used to amplify or to extend sequences using divergent primers based on a known region (Triglia, T. *et al.* (1988) 20 Nucleic Acids Res. 16:8186). Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. *et al.* (1991) PCR Methods Applic., 1, 111-119). Another method which may be used to retrieve unknown sequences is that of Parker, J.D. *et al.* (1991); Nucleic Acids Res. 19:3055-3060). Additionally, one may use 25 PCR, nested primers, and PromoterFinder<sup>TM</sup> libraries to walk genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that 30 they will contain more sequences that contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

In one embodiment of the invention, the nucleic acid molecules of the present invention may be used for chromosome localisation. In this technique, a nucleic acid molecule is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the 5 present invention is an important step in the confirmatory correlation of those sequences with the gene-associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch 10 Medical Library). The relationships between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes). This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localised by genetic linkage to a particular 15 genomic region, any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleic acid molecule may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

The nucleic acid molecules of the present invention are also valuable for tissue 20 localisation. Such techniques allow the determination of expression patterns of the polypeptide in tissues by detection of the mRNAs that encode them. These techniques include *in situ* hybridization techniques and nucleotide amplification techniques, such as PCR. Results from these studies provide an indication of the normal functions of the 25 polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by a mutant gene provide valuable insights into the role of mutant polypeptides in disease. Such inappropriate expression may be of a temporal, spatial or quantitative nature.

The vectors of the present invention comprise nucleic acid molecules of the invention and 30 may be cloning or expression vectors. The host cells of the invention, which may be transformed, transfected or transduced with the vectors of the invention may be prokaryotic or eukaryotic.

The polypeptides of the invention may be prepared in recombinant form by expression of

their encoding nucleic acid molecules in vectors contained within a host cell. Such expression methods are well known to those of skill in the art and many are described in detail by Sambrook *et al.* (*supra*) and Fernandez & Hoeffler (1998, eds. "Gene expression systems. Using nature for the art of expression". Academic Press, San Diego, London, 5 Boston, New York, Sydney, Tokyo, Toronto).

Generally, any system or vector that is suitable to maintain, propagate or express nucleic acid molecules to produce a polypeptide in the required host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those described in Sambrook *et al.*, 10 (*supra*). Generally, the encoding gene can be placed under the control of a control element such as a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator, so that the DNA sequence encoding the desired polypeptide is transcribed into RNA in the transformed host cell.

Examples of suitable expression systems include, for example, chromosomal, episomal and 15 virus-derived systems, including, for example, vectors derived from: bacterial plasmids, bacteriophage, transposons, yeast episomes, insertion elements, yeast chromosomal elements, viruses such as baculoviruses, papova viruses such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, or combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, including 20 cosmids and phagemids. Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid.

Particularly suitable expression systems include microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus 25 expression vectors (for example, baculovirus); plant cell systems transformed with virus expression vectors (for example, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (for example, Ti or pBR322 plasmids); or animal cell systems. Cell-free translation systems can also be employed to produce the polypeptides of the invention.

30 Introduction of nucleic acid molecules encoding a polypeptide of the present invention into host cells can be effected by methods described in many standard laboratory manuals, such as Davis *et al.*, Basic Methods in Molecular Biology (1986) and Sambrook *et al.*, (*supra*).

Particularly suitable methods include calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection (see Sambrook *et al.*, 1989 [*supra*]; Ausubel *et al.*, 1991 [*supra*]; Spector, Goldman & Leinwald, 1998). In eukaryotic cells, expression systems may either be transient (for example, episomal) or permanent (chromosomal integration) according to the needs of the system.

The encoding nucleic acid molecule may or may not include a sequence encoding a control sequence, such as a signal peptide or leader sequence, as desired, for example, for secretion of the translated polypeptide into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals. Leader sequences can be removed by the bacterial host in post-translational processing.

In addition to control sequences, it may be desirable to add regulatory sequences that allow for regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory sequences are those which cause the expression of a gene to be increased or decreased in response to a chemical or physical stimulus, including the presence of a regulatory compound or to various temperature or metabolic conditions. Regulatory sequences are those non-translated regions of the vector, such as enhancers, promoters and 5' and 3' untranslated regions. These interact with host cellular proteins to carry out transcription and translation. Such regulatory sequences may vary in their strength and specificity. Depending on the vector system and host utilised, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript phagemid (Stratagene, LaJolla, CA) or pSport<sup>TM</sup> plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (for example, heat shock, RUBISCO and storage protein genes) or from plant viruses (for example, viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

- An expression vector is constructed so that the particular nucleic acid coding sequence is located in the vector with the appropriate regulatory sequences, the positioning and orientation of the coding sequence with respect to the regulatory sequences being such that the coding sequence is transcribed under the "control" of the regulatory sequences, i.e.,
- 5 RNA polymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence. In some cases it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame.

The control sequences and other regulatory sequences may be ligated to the nucleic acid  
10 coding sequence prior to insertion into a vector. Alternatively, the coding sequence can be cloned directly into an expression vector that already contains the control sequences and an appropriate restriction site.

For long-term, high-yield production of a recombinant polypeptide, stable expression is preferred. For example, cell lines which stably express the polypeptide of interest may be  
15 transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and  
20 recovery of cells that successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Mammalian cell lines available as hosts for expression are known in the art and include many immortalised cell lines available from the American Type Culture Collection  
25 (ATCC) including, but not limited to, Chinese hamster ovary (CHO), HeLa, baby hamster kidney (BHK), monkey kidney (COS), C127, 3T3, BHK, HEK 293, Bowes melanoma and human hepatocellular carcinoma (for example Hep G2) cells and a number of other cell lines.

In the baculovirus system, the materials for baculovirus/insect cell expression systems are  
30 commercially available in kit form from, *inter alia*, Invitrogen, San Diego CA (the "MaxBac" kit). These techniques are generally known to those skilled in the art and are described fully in Summers and Smith, Texas Agricultural Experiment Station Bulletin No.

1555 (1987). Particularly suitable host cells for use in this system include insect cells such as *Drosophila S2* and *Spodoptera Sf9* cells.

There are many plant cell culture and whole plant genetic expression systems known in the art. Examples of suitable plant cellular genetic expression systems include those described 5 in US 5,693,506; US 5,659,122; and US 5,608,143. Additional examples of genetic expression in plant cell culture has been described by Zenk, *Phytochemistry* 30, 3861-3863 (1991).

In particular, all plants from which protoplasts can be isolated and cultured to give whole regenerated plants can be utilised, so that whole plants are recovered which contain the 10 transferred gene. Practically all plants can be regenerated from cultured cells or tissues, including but not limited to all major species of sugar cane, sugar beet, cotton, fruit and other trees, legumes and vegetables.

Examples of particularly preferred bacterial host cells include *streptococci*, *staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells.

15 Examples of particularly suitable host cells for fungal expression include yeast cells (for example, *S. cerevisiae*) and *Aspergillus* cells.

Any number of selection systems are known in the art that may be used to recover transformed cell lines. Examples include the herpes simplex virus thymidine kinase (Wigler, M. *et al.* (1977) *Cell* 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. 20 *et al.* (1980) *Cell* 22:817-23) genes that can be employed in tk<sup>-</sup> or aprt<sup>±</sup> cells, respectively.

Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dihydrofolate reductase (DHFR) that confers resistance to methotrexate (Wigler, M. *et al.* (1980) *Proc. Natl. Acad. Sci.* 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. *et al.* 25 (1981) *J. Mol. Biol.* 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. Additional selectable genes have been described, examples of which will be clear to those of skill in the art.

Although the presence or absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For 30 example, if the relevant sequence is inserted within a marker gene sequence, transformed cells containing the appropriate sequences can be identified by the absence of marker gene

function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a polypeptide of the invention under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

- 5   Alternatively, host cells that contain a nucleic acid sequence encoding a polypeptide of the invention and which express said polypeptide may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassays, for example, fluorescence activated cell sorting (FACS) or immunoassay techniques (such as the enzyme-linked
- 10   immunosorbent assay [ELISA] and radioimmunoassay [RIA]), that include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein (see Hampton, R. *et al.* (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul, MN) and Maddox, D.E. *et al.* (1983) J. Exp. Med., 158, 1211-1216).

- A wide variety of labels and conjugation techniques are known by those skilled in the art
- 15   and may be used in various nucleic acid and amino acid assays. Means for producing labelled hybridization or PCR probes for detecting sequences related to nucleic acid molecules encoding polypeptides of the present invention include oligolabelling, nick translation, end-labelling or PCR amplification using a labelled polynucleotide. Alternatively, the sequences encoding the polypeptide of the invention may be cloned into
  - 20   a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesise RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labelled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp.,
  - 25   Cleveland, OH)).

Suitable reporter molecules or labels, which may be used for ease of detection, include radionuclides, enzymes and fluorescent, chemiluminescent or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

- Nucleic acid molecules according to the present invention may also be used to create
- 30   transgenic animals, particularly rodent animals. Such transgenic animals form a further aspect of the present invention. This may be done locally by modification of somatic cells, or by germ line therapy to incorporate heritable modifications. Such transgenic animals

may be particularly useful in the generation of animal models for drug molecules effective as modulators of the polypeptides of the present invention.

The polypeptide can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulphate or ethanol precipitation, acid extraction, 5 anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. High performance liquid chromatography is particularly useful for purification. Well known techniques for refolding proteins may be employed to regenerate an active conformation when the polypeptide is denatured during 10 isolation and or purification.

Specialised vector constructions may also be used to facilitate purification of proteins, as desired, by joining sequences encoding the polypeptides of the invention to a nucleotide sequence encoding a polypeptide domain that will facilitate purification of soluble proteins. Examples of such purification-facilitating domains include metal chelating, 15 peptides such as histidine-tryptophan modules that allow purification on immobilised metals, protein A domains that allow purification on immobilised immunoglobulin, and the domain utilised in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the 20 polypeptide of the invention may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing the polypeptide of the invention fused to several histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC (immobilised metal ion affinity chromatography as described in Porath, J. *et al.* (1992), Prot. Exp. Purif. 3: 25 263-281) while the thioredoxin or enterokinase cleavage site provides a means for purifying the polypeptide from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. *et al.* (1993; DNA Cell Biol. 12:441-453).

If the polypeptide is to be expressed for use in screening assays, generally it is preferred that it be produced at the surface of the host cell in which it is expressed. In this event, the 30 host cells may be harvested prior to use in the screening assay, for example using techniques such as fluorescence activated cell sorting (FACS) or immunoaffinity techniques. If the polypeptide is secreted into the medium, the medium can be recovered in

order to recover and purify the expressed polypeptide. If polypeptide is produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

The polypeptide of the invention can be used to screen libraries of compounds in any of a variety of drug screening techniques. Such compounds may activate (agonise) or inhibit

5 (antagonise) the level of expression of the gene or the activity of the polypeptide of the invention and form a further aspect of the present invention. Preferred compounds are effective to alter the expression of a natural gene which encodes a polypeptide of the first aspect of the invention or to regulate the activity of a polypeptide of the first aspect of the invention.

10 Agonist or antagonist compounds may be isolated from, for example, cells, cell-free preparations, chemical libraries or natural product mixtures. These agonists or antagonists may be natural or modified substrates, ligands, enzymes, receptors or structural or functional mimetics. For a suitable review of such screening techniques, see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991).

15 Compounds that are most likely to be good antagonists are molecules that bind to the polypeptide of the invention without inducing the biological effects of the polypeptide upon binding to it. Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to the polypeptide of the invention and thereby inhibit or extinguish its activity. In this fashion, binding of the polypeptide to normal  
20 cellular binding molecules may be inhibited, such that the normal biological activity of the polypeptide is prevented.

The polypeptide of the invention that is employed in such a screening technique may be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly.

In general, such screening procedures may involve using appropriate cells or cell

25 membranes that express the polypeptide that are contacted with a test compound to observe binding, or stimulation or inhibition of a functional response. The functional response of the cells contacted with the test compound is then compared with control cells that were not contacted with the test compound. Such an assay may assess whether the test compound results in a signal generated by activation of the polypeptide, using an  
30 appropriate detection system. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist in the presence of the test compound is observed.

A preferred method for identifying an agonist or antagonist compound of a polypeptide of the present invention comprises:

- (a) contacting a cell expressing on the surface thereof the polypeptide according to the first aspect of the invention, the polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to the polypeptide, with a compound to be screened under conditions to permit binding to the polypeptide; and
- 5 (b) determining whether the compound binds to and activates or inhibits the polypeptide by measuring the level of a signal generated from the interaction of the compound with the polypeptide.
- 10

A further preferred method for identifying an agonist or antagonist of a polypeptide of the invention comprises:

- (a) contacting a cell expressing on the surface thereof the polypeptide, the polypeptide being associated with a second component capable of providing a detectable signal in response to the binding of a compound to the polypeptide, with a compound to be screened under conditions to permit binding to the polypeptide; and
- 15 (b) determining whether the compound binds to and activates or inhibits the polypeptide by comparing the level of a signal generated from the interaction of the compound with the polypeptide with the level of a signal in the absence of the compound.
- 20 In further preferred embodiments, the general methods that are described above may further comprise conducting the identification of agonist or antagonist in the presence of labelled or unlabelled ligand for the polypeptide.
- In another embodiment of the method for identifying an agonist or antagonist of a polypeptide of the present invention comprises:
- 25 determining the inhibition of binding of a ligand to cells which have a polypeptide of the invention on the surface thereof, or to cell membranes containing such a polypeptide, in the presence of a candidate compound under conditions to permit binding to the polypeptide, and determining the amount of ligand bound to the polypeptide. A compound capable of causing reduction of binding of a ligand is considered to be an agonist or
- 30 antagonist. Preferably the ligand is labelled.

More particularly, a method of screening for a polypeptide antagonist or agonist compound

comprises the steps of:

- (a) incubating a labelled ligand with a whole cell expressing a polypeptide according to the invention on the cell surface, or a cell membrane containing a polypeptide of the invention,
- (b) measuring the amount of labelled ligand bound to the whole cell or the cell membrane;
- 5 (c) adding a candidate compound to a mixture of labelled ligand and the whole cell or the cell membrane of step (a) and allowing the mixture to attain equilibrium;
- (d) measuring the amount of labelled ligand bound to the whole cell or the cell membrane after step (c); and
- (e) comparing the difference in the labelled ligand bound in step (b) and (d), such that the
- 10 compound which causes the reduction in binding in step (d) is considered to be an agonist or antagonist.

In certain of the embodiments described above, simple binding assays may be used, in which the adherence of a test compound to a surface bearing the polypeptide is detected by means of a label directly or indirectly associated with the test compound or in an assay

15 involving competition with a labelled competitor. In another embodiment, competitive drug screening assays may be used, in which neutralising antibodies that are capable of binding the polypeptide specifically compete with a test compound for binding. In this manner, the antibodies can be used to detect the presence of any test compound that possesses specific binding affinity for the polypeptide.

- 20 Assays may also be designed to detect the effect of added test compounds on the production of mRNA encoding the polypeptide in cells. For example, an ELISA may be constructed that measures secreted or cell-associated levels of polypeptide using monoclonal or polyclonal antibodies by standard methods known in the art, and this can be used to search for compounds that may inhibit or enhance the production of the
- 25 polypeptide from suitably manipulated cells or tissues. The formation of binding complexes between the polypeptide and the compound being tested may then be measured using assays such as ProCheck™ Universal Protease Assay (Serologicals Corporation), EnzChek Protease Assay (Molecular Probes) or Protease Activity Detection Kit (PanVera). Another technique for drug screening which may be used provides for high throughput
- 30 screening of compounds having suitable binding affinity to the polypeptide of interest (see

International patent application WO84/03564). In this method, large numbers of different small test compounds are synthesised on a solid substrate, which may then be reacted with the polypeptide of the invention and washed. One way of immobilising the polypeptide is to use non-neutralising antibodies. Bound polypeptide may then be detected using methods 5 that are well known in the art. Purified polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques.

The polypeptide of the invention may be used to identify membrane-bound or soluble receptors, through standard receptor binding techniques that are known in the art, such as ligand binding and crosslinking assays in which the polypeptide is labelled with a 10 radioactive isotope, is chemically modified, or is fused to a peptide sequence that facilitates its detection or purification, and incubated with a source of the putative receptor (for example, a composition of cells, cell membranes, cell supernatants, tissue extracts, or bodily fluids). The efficacy of binding may be measured using biophysical techniques such as surface plasmon resonance and spectroscopy. Binding assays may be used for the 15 purification and cloning of the receptor, but may also identify agonists and antagonists of the polypeptide, that compete with the binding of the polypeptide to its receptor. Standard methods for conducting screening assays are well understood in the art.

The invention also includes a screening kit useful in the methods for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, that are described above.

20 The invention includes the agonists, antagonists, ligands, receptors, substrates and enzymes, and other compounds which modulate the activity or antigenicity of the polypeptide of the invention discovered by the methods that are described above.

The invention also provides pharmaceutical compositions comprising a polypeptide, nucleic acid, ligand or compound of the invention in combination with a suitable 25 pharmaceutical carrier. These compositions may be suitable as therapeutic or diagnostic reagents, as vaccines, or as other immunogenic compositions, as outlined in detail below.

According to the terminology used herein, a composition containing a polypeptide, nucleic acid, ligand or compound [X] is "substantially free of" impurities [herein, Y] when at least 85% by weight of the total X+Y in the composition is X. Preferably, X comprises at least 30 about 90% by weight of the total of X+Y in the composition, more preferably at least about 95%, 98% or even 99% by weight.

The pharmaceutical compositions should preferably comprise a therapeutically effective amount of the polypeptide, nucleic acid molecule, ligand, or compound of the invention. The term "therapeutically effective amount" as used herein refers to an amount of a therapeutic agent needed to treat, ameliorate, or prevent a targeted disease or condition, or

5 to exhibit a detectable therapeutic or preventative effect. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, for example, of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes

10 for administration in humans.

The precise effective amount for a human subject will depend upon the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. This amount can be determined by routine experimentation

15 and is within the judgement of the clinician. Generally, an effective dose will be from 0.01 mg/kg to 50 mg/kg, preferably 0.05 mg/kg to 10 mg/kg. Compositions may be administered individually to a patient or may be administered in combination with other agents, drugs or hormones.

A pharmaceutical composition may also contain a pharmaceutically acceptable carrier, for

20 administration of a therapeutic agent. Such carriers include antibodies and other polypeptides, genes and other therapeutic agents such as liposomes, provided that the carrier does not itself induce the production of antibodies harmful to the individual receiving the composition, and which may be administered without undue toxicity. Suitable carriers may be large, slowly metabolised macromolecules such as proteins,

25 polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.

Pharmaceutically acceptable salts can be used therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulphates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough

30 discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).

Pharmaceutically acceptable carriers in therapeutic compositions may additionally contain

liquids such as water, saline, glycerol and ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such compositions. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like,  
5 for ingestion by the patient.

Once formulated, the compositions of the invention can be administered directly to the subject. The subjects to be treated can be animals; in particular, human subjects can be treated.

The pharmaceutical compositions utilised in this invention may be administered by any  
10 number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal or transcutaneous applications (for example, see WO98/20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal or rectal means. Gene guns or hyposprays may also be used to administer the pharmaceutical compositions of the invention. Typically, the  
15 therapeutic compositions may be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.

Direct delivery of the compositions will generally be accomplished by injection, subcutaneously, intraperitoneally, intravenously or intramuscularly, or delivered to the  
20 interstitial space of a tissue. The compositions can also be administered into a lesion. Dosage treatment may be a single dose schedule or a multiple dose schedule.

If the activity of the polypeptide of the invention is in excess in a particular disease state, several approaches are available. One approach comprises administering to a subject an inhibitor compound (antagonist) as described above, along with a pharmaceutically  
25 acceptable carrier in an amount effective to inhibit the function of the polypeptide, such as by blocking the binding of ligands, substrates, enzymes, receptors, or by inhibiting a second signal, and thereby alleviating the abnormal condition. Preferably, such antagonists are antibodies. Most preferably, such antibodies are chimeric and/or humanised to minimise their immunogenicity, as described previously.

30 In another approach, soluble forms of the polypeptide that retain binding affinity for the ligand, substrate, enzyme, receptor, in question, may be administered. Typically, the polypeptide may be administered in the form of fragments that retain the relevant portions.

In an alternative approach, expression of the gene encoding the polypeptide can be inhibited using expression blocking techniques, such as the use of antisense nucleic acid molecules (as described above), either internally generated or separately administered. Modifications of gene expression can be obtained by designing complementary sequences 5 or antisense molecules (DNA, RNA, or PNA) to the control, 5' or regulatory regions (signal sequence, promoters, enhancers and introns) of the gene encoding the polypeptide. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules.

10 Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. *et al.* (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Such oligonucleotides may be administered or may be

15 generated *in situ* from expression *in vivo*.

In addition, expression of the polypeptide of the invention may be prevented by using ribozymes specific to its encoding mRNA sequence. Ribozymes are catalytically active RNAs that can be natural or synthetic (see for example Usman, N, *et al.*, Curr. Opin. Struct. Biol (1996) 6(4), 527-33). Synthetic ribozymes can be designed to specifically 20 cleave mRNAs at selected positions thereby preventing translation of the mRNAs into functional polypeptide. Ribozymes may be synthesised with a natural ribose phosphate backbone and natural bases, as normally found in RNA molecules. Alternatively the ribozymes may be synthesised with non-natural backbones, for example, 2'-O-methyl RNA, to provide protection from ribonuclease degradation and may contain modified 25 bases.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent 30 in the production of PNAs and can be extended in all of these molecules by the inclusion of non-traditional bases such as inosine, queosine and butosine, as well as acetyl-, methyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine and uridine which are not as easily recognised by endogenous endonucleases.

For treating abnormal conditions related to an under-expression of the polypeptide of the invention and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound that activates the polypeptide, i.e., an agonist as described above, to alleviate the abnormal condition.

- 5 Alternatively, a therapeutic amount of the polypeptide in combination with a suitable pharmaceutical carrier may be administered to restore the relevant physiological balance of polypeptide.

Gene therapy may be employed to effect the endogenous production of the polypeptide by the relevant cells in the subject. Gene therapy is used to treat permanently the inappropriate 10 production of the polypeptide by replacing a defective gene with a corrected therapeutic gene.

- 15 Gene therapy of the present invention can occur *in vivo* or *ex vivo*. *Ex vivo* gene therapy requires the isolation and purification of patient cells, the introduction of a therapeutic gene and introduction of the genetically altered cells back into the patient. In contrast, *in vivo* gene therapy does not require isolation and purification of a patient's cells.

The therapeutic gene is typically "packaged" for administration to a patient. Gene delivery vehicles may be non-viral, such as liposomes, or replication-deficient viruses, such as adenovirus as described by Berkner, K.L., in Curr. Top. Microbiol. Immunol., 158, 39-66 (1992) or adeno-associated virus (AAV) vectors as described by Muzyczka, N., in Curr. 20 Top. Microbiol. Immunol., 158, 97-129 (1992) and U.S. Patent No. 5,252,479. For example, a nucleic acid molecule encoding a polypeptide of the invention may be engineered for expression in a replication-defective retroviral vector. This expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding the polypeptide, such that the 25 packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo* (see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics (1996), T Strachan and A P Read, BIOS Scientific Publishers Ltd).

30 Another approach is the administration of "naked DNA" in which the therapeutic gene is directly injected into the bloodstream or muscle tissue.

In situations in which the polypeptides or nucleic acid molecules of the invention are

disease-causing agents, the invention provides that they can be used in vaccines to raise antibodies against the disease causing agent.

Vaccines according to the invention may either be prophylactic (i.e. to prevent infection) or therapeutic (i.e. to treat disease after infection). Such vaccines comprise immunising 5 antigen(s), immunogen(s), polypeptide(s), protein(s) or nucleic acid, usually in combination with pharmaceutically-acceptable carriers as described above, which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen or immunogen may be conjugated to a 10 bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, *H. pylori*, and other pathogens.

Since polypeptides may be broken down in the stomach, vaccines comprising polypeptides are preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration 15 include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient, and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents.

The vaccine formulations of the invention may be presented in unit-dose or multi-dose 20 containers. For example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

This invention also relates to the use of nucleic acid molecules according to the present 25 invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the nucleic acid molecules of the invention which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may 30 be detected at the DNA level by a variety of techniques.

Nucleic acid molecules for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used

directly for detection or may be amplified enzymatically by using PCR, ligase chain reaction (LCR), strand displacement amplification (SDA), or other amplification techniques (see Saiki *et al.*, Nature, 324, 163-166 (1986); Bej, *et al.*, Crit. Rev. Biochem. Molec. Biol., 26, 301-334 (1991); Birkenmeyer *et al.*, J. Virol. Meth., 35, 117-126 (1991);  
5 Van Brunt, J., Bio/Technology, 8, 291-294 (1990)) prior to analysis.

In one embodiment, this aspect of the invention provides a method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to the invention and comparing said level of expression to a control level, wherein a level that is different to said control level is indicative of disease. The  
10 method may comprise the steps of:

- a)contacting a sample of tissue from the patient with a nucleic acid probe under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule of the invention and the probe;
- b)contacting a control sample with said probe under the same conditions used in step a);  
15 c)and detecting the presence of hybrid complexes in said samples;

wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease.

A further aspect of the invention comprises a diagnostic method comprising the steps of:

- a)obtaining a tissue sample from a patient being tested for disease;
- b)isolating a nucleic acid molecule according to the invention from said tissue sample; and  
20 c)diagnosing the patient for disease by detecting the presence of a mutation in the nucleic acid molecule which is associated with disease.

To aid the detection of nucleic acid molecules in the above-described methods, an amplification step, for example using PCR, may be included.

- 25 Deletions and insertions can be detected by a change in the size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labelled RNA of the invention or alternatively, labelled antisense DNA sequences of the invention. Perfectly-matched sequences can be distinguished from mismatched duplexes by RNase digestion or by assessing differences in melting  
30 temperatures. The presence or absence of the mutation in the patient may be detected by

- contacting DNA with a nucleic acid probe that hybridises to the DNA under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence  
5 of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation in the corresponding portion of the DNA strand.

Such diagnostics are particularly useful for prenatal and even neonatal testing.

- Point mutations and other sequence differences between the reference gene and "mutant" genes can be identified by other well-known techniques, such as direct DNA sequencing or  
10 single-strand conformational polymorphism, (see Orita *et al.*, Genomics, 5, 874-879 (1989)). For example, a sequencing primer may be used with double-stranded PCR product or a single-stranded template molecule generated by a modified PCR. The sequence determination is performed by conventional procedures with radiolabelled nucleotides or by automatic sequencing procedures with fluorescent-tags. Cloned DNA segments may  
15 also be used as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. Further, point mutations and other sequence variations, such as polymorphisms, can be detected as described above, for example, through the use of allele-specific oligonucleotides for PCR amplification of sequences that differ by single nucleotides.  
20 DNA sequence differences may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (for example, Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc. Natl. Acad. Sci.  
25 USA (1985) 85: 4397-4401).

- In addition to conventional gel electrophoresis and DNA sequencing, mutations such as microdeletions, aneuploidies, translocations, inversions, can also be detected by *in situ* analysis (see, for example, Keller *et al.*, DNA Probes, 2nd Ed., Stockton Press, New York, N.Y., USA (1993)), that is, DNA or RNA sequences in cells can be analysed for mutations  
30 without need for their isolation and/or immobilisation onto a membrane. Fluorescence *in situ* hybridization (FISH) is presently the most commonly applied method and numerous reviews of FISH have appeared (see, for example, Trachuck *et al.*, Science, 250, 559-562

(1990), and Trask *et al.*, Trends, Genet., 7, 149-154 (1991)).

In another embodiment of the invention, an array of oligonucleotide probes comprising a nucleic acid molecule according to the invention can be constructed to conduct efficient screening of genetic variants, mutations and polymorphisms. Array technology methods 5 are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee *et al.*, Science (1996), Vol 274, pp 610-613).

In one embodiment, the array is prepared and used according to the methods described in PCT application WO95/11995 (Chee *et al*); Lockhart, D. J. *et al.* (1996) Nat. Biotech. 14: 10 1675-1680); and Schena, M. *et al.* (1996) Proc. Natl. Acad. Sci. 93: 10614-10619).

Oligonucleotide pairs may range from two to over one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support. In another aspect, an oligonucleotide may be synthesized on 15 the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/25116 (Baldeschweiler *et al.*). In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such 20 as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536 or 6144 oligonucleotides, or any other number between two and over one million which lends itself to the efficient use of commercially-available instrumentation.

25 In addition to the methods discussed above, diseases may be diagnosed by methods comprising determining, from a sample derived from a subject, an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for 30 instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.

Assay techniques that can be used to determine levels of a polypeptide of the present

invention in a sample derived from a host are well-known to those of skill in the art and are discussed in some detail above (including radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays). This aspect of the invention provides a diagnostic method which comprises the steps of: (a) contacting a ligand as described above  
5 with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.

Protocols such as ELISA, RIA, and FACS for measuring polypeptide levels may additionally provide a basis for diagnosing altered or abnormal levels of polypeptide expression. Normal or standard values for polypeptide expression are established by  
10 combining body fluids or cell extracts taken from normal mammalian subjects, preferably humans, with antibody to the polypeptide under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, such as by photometric means.

Antibodies which specifically bind to a polypeptide of the invention may be used for the  
15 diagnosis of conditions or diseases characterised by expression of the polypeptide, or in assays to monitor patients being treated with the polypeptides, nucleic acid molecules, ligands and other compounds of the invention. Antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for the polypeptide include methods that utilise the antibody and a label to detect  
20 the polypeptide in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labelled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules known in the art may be used, several of which are described above.

Quantities of polypeptide expressed in subject, control and disease samples from biopsied  
25 tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease. Diagnostic assays may be used to distinguish between absence, presence, and excess expression of polypeptide and to monitor regulation of polypeptide levels during therapeutic intervention. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal  
30 studies, in clinical trials or in monitoring the treatment of an individual patient.

A diagnostic kit of the present invention may comprise:

(a) a nucleic acid molecule of the present invention;

(b) a polypeptide of the present invention; or

(c) a ligand of the present invention.

In one aspect of the invention, a diagnostic kit may comprise a first container containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to the invention; a second container containing primers useful for amplifying the nucleic acid molecule; and instructions for using the probe and primers for facilitating the diagnosis of disease. The kit may further comprise a third container holding an agent for digesting unhybridised RNA.

In an alternative aspect of the invention, a diagnostic kit may comprise an array of nucleic acid molecules, at least one of which may be a nucleic acid molecule according to the invention.

To detect polypeptide according to the invention, a diagnostic kit may comprise one or more antibodies that bind to a polypeptide according to the invention; and a reagent useful for the detection of a binding reaction between the antibody and the polypeptide.

Such kits will be of use in diagnosing a disease or susceptibility to disease in which members of the trypsin family of proteins are implicated. Such diseases may include cell proliferative disorders and/or differentiative disorders, such as carcinoma, sarcoma, solid tumours including prostate, breast, lung, testis, ovary, head and neck, brain or bone tumour, metastatic disorders or hematopoietic neoplastic disorders; disorders of bone metabolism, such as osteoporosis, osteodystrophy, osteomalacia, rickets, osteitis fibrosa cystica, renal osteodystrophy, osteosclerosis, osteopenia, fibrogenesis-imperfecta ossium, secondary hyperparathyroidism, hypoparathyroidism, hyperparathyroidism; periodontal disease, immune/autoimmune disorders such as, arthritis, multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus erythematosus, autoimmune thyroiditis, dermatitis, psoriasis, Sjogren's Syndrome, Crohn's disease, ulcer, iritis, conjunctivitis, ulcerative colitis, asthma, scleroderma, autoimmune uveitis, allergic encephalomyelitis, hearing loss, aplastic anemia, anemia, idiopathic thrombocytopenia, polychondritis, Graves' disease, graft-versus-host disease, allergy; hematopoietic disorders; cardiovascular disorders such as hypertension, atherosclerosis, congestive heart failure, coronary artery disease, arrhythmias, cardiomyopathies, arteriosclerosis, hypertensive vascular disease, Raynaud disease, aneurysms, varicose veins, thrombophlebitis, phlebothrombosis, tumors, hemangioma, lymphangioma, glomus tumor (glomangioma),

Kaposi sarcoma, angiosarcoma, hemangiopericytoma; blood clotting disorders, such as hemorrhagic diatheses, nonthrombocytopenic purpuras, thrombocytopenia, idiopathic thrombocytopenic purpura, HIV-associated thrombocytopenia, thrombotic microangiopathies, hemorrhagic diatheses, lymphomas, Hodgkin disease; liver disorders such as, cirrhosis, hepatocellular necrosis, liver fibrosis, Al-antitrypsin deficiency, hemochromatosis copper storage diseases and liver damage (especially drug or alcohol induced); bacterial, fungal or viral infection; pain or metabolic disorders, such as obesity, anorexia nervosa, cachexia, lipid disorders, and diabetes; AIDS and other pathological conditions.

10 Preferably, the diseases are those in which members of the trypsin family are implicated.

Various aspects and embodiments of the present invention will now be described in more detail by way of example, with particular reference to the INTP039 polypeptides.

It will be appreciated that modification of detail may be made without departing from the scope of the invention.

## 15 Brief description of the Figures

**Figure 1:** BLASTP output for INTP039 polypeptide sequence (SEQ ID NO: 22) against the NCBI non-redundant database.

**Figure 2:** Alignment between INTP039 polypeptide sequence (SEQ ID NO:22) and the BLASTP hit, NP\_114154.1 (*Homo sapiens*).

20 **Figure 3:** SigP cleavage site prediction for INTP039.

**Figure 4:** INTP039 domain organisation

**Figure 5:** INTP039 polypeptide multiple sequence alignment

**Figure 6:** Predicted model of INTP039 domains 1 and 2

### Examples

#### Example 1: INTP039 BLAST Results

The INTP039 polypeptide sequence (SEQ ID NO:22) was used as a protein BLAST query sequence against the NCBI non-redundant sequence database. Figure 1 shows the top ten results for the BLASTP query, and Figure 2 shows the alignment against NP\_114154.1 (*Homo sapiens*).

#### Example 2: INTP039 signal sequence

Figure 3 show that INTP039 is predicted to possess a signal peptide at the start of the protein. As the SigP data in Figure 3 clearly shows, the signal peptide cleavage site is thought to be between residues 23 and 24 of the INTP039 polypeptide sequence (Nielsen, H. et al. 1997, Protein Engineering, 10, 1-6; Nielsen, H., and Krogh, A.: Prediction of signal peptides and signal anchors by a hidden Markov model. In Proceedings of the Sixth International Conference on Intelligent Systems for Molecular Biology (ISMB 6), AAAI Press, Menlo Park, California, pp. 122-130 (1998)).

#### Example 3: INTP039 structure

Figure 4 shows that it is predicted that the INTP039 polypeptide contains two trypsin domains. Figure 5 shows the predicted structure of the two trypsin domains that are found within INTP039. Figure 6 shows INTP039 aligned against other proteins that contain such domains.

#### Example 4: EST data

Table 2 describes expressed sequence tags (ESTs) which have homology to the INTP039 transcript. Based on the cDNA libraries from which the EST's originate, INTP039 appears to be expressed in the tissues listed in Table1.

Accession number	Source	Organism
BE792289	Lung	Homo sapiens
Z42936	Brain	Homo sapiens
R18052	Brain	Homo sapiens
BE264142	Lung	Homo sapiens
BQ437135	Eye	Homo sapiens

Table 2: ESTs identified as having homology with INTP039

**Sequence Listing:****SEQ ID NO: 1 (INTP039 nucleotide sequence exon 1)**

1 ATGAAGTGGT GCTGGGGCCC AGTGCTGCTC ATCGCGGGTG CCACAGTCCT  
 51 CATGGAGG

5

**SEQ ID NO: 2 (INTP039 polypeptide sequence exon 1)**

1 MKWCWGPVILL IAGATVLMEG

**SEQ ID NO: 3 (INTP039 nucleotide sequence exon 2)**

10 1 GTCTTCAAGC CGCTCAGCGT G

**SEQ ID NO: 4 (INTP039 polypeptide sequence exon 2)**

1 LQAAQRA

**15 SEQ ID NO: 5 (INTP039 nucleotide sequence exon 3)**

1 CCTGTGGACA GCGTGGCCCC GGCCCCCCC AGCCTCAGGA GGGCAACACA  
 51 GTCCCTGGCG AGTGGCCCTG GCAGGCCAGT GTGAGGAGGC AAGGAGCCCA  
 101 CATCTGCAGC GGCTCCCTGG TGGCAGACAC CTGGGTCCCTC ACTGCTGCC  
 151 ACTGCTTTGA AAA

20

**SEQ ID NO: 6 (INTP039 polypeptide sequence exon 3)**

1 CGQRGPGPDK PQEGNTVPGE WPWQASVRRQ GAHICSGSLV ADTWVLTAHH  
 51 CFEK

**25 SEQ ID NO: 7 (INTP039 nucleotide sequence exon 4)**

1 GGCAGGAGCA ACAGAACTGA ATTCCCTGGTC AGTGGTCCTG GGTTCTCTGC  
 51 AGCGTGAGGG ACTCAGCCCT GGGGCCGAAG AGGTGGGGGT GGCTGCCCTG  
 101 CAGTTGCCCA GGGCCTATAA CCACTACAGC CAGGGCTCAG ACCTGGCCCT  
 151 GCTGCAGCTC GCCCACCCCA CGACCCACAC ACCCCTCTGC CTGCCCCAGC  
 201 CCGCCCATCG CTTCCCCTTT GGAGCCTCCT GCTGGGCCAC TGGCTGGGAT  
 251 CAGGACACCA GTGATG

**SEQ ID NO: 8 (INTP039 polypeptide sequence exon 4)**

1 AAATELNSWS VVLGSLQREG LSPGAEEVGV AALQLPRAYN HYSQGSDLAL  
 35 51 LQLAHPTTHT PLCLPQPAHR FPFGASCWAT GWDQDTSDA

**SEQ ID NO: 9 (INTP039 nucleotide sequence exon 5)**

1 CTCCTGGGAC CCTACGCAAT CTGCGCCTGC GTCTCATCAG TCGCCCCACA

51 TGTAACGTGA TCTACAACCA GCTGCACCAG CGACACCTGT CCAACCCGGC  
 101 CCGGCCTGGG ATGCTATGTG GGGGCCCCCA GCCTGGGTG CAGGGCCCCT  
 151 GTCAG

**5 SEQ ID NO: 10 (INTP039 polypeptide sequence exon 5)**

1 PGTLLRNLLRR LISRPTCNCI YNQLHQRHLS NPARPGMLCG GPQPGVQGPC  
 51 Q

**SEQ ID NO: 11 (INTP039 nucleotide sequence exon 6)**

10 1 GGAGATTCCG GGGGCCCTGT GCTGTGCCTC GAGCCTGACG GACACTGGGT  
 51 TCAGGCTGGC ATCATCAGCT TTGCATCAAG CTGTGCCAG GAGGACGCTC  
 101 CTGTGCTGCT GACCAACACA GCTGCTCAC A GTTCCTGGCT GCAGGCTCGA  
 151 GTTCAGGGGG CAGCTTCCT GCCCCAGAGC CCAGAGACCC CGGAGATGAG  
 201 TGATGAGGAC AGCTGTGTAG

15

**SEQ ID NO: 12 (INTP039 polypeptide sequence exon 6)**

1 GDSGGPVLCI EPDGHWVQAG IISFASSCAQ EDAPVLLTNT AAHSSWLQAR  
 51 VQGAAFLAQI PETPEMSDED SCVA

**20 SEQ ID NO: 13 (INTP039 nucleotide sequence exon 7)**

1 CCTGTGGATC CTTGAGGACA GCAGGTCCCC AGGCAGGAGC ACCCTCCCCA  
 51 TGGCCCTGGG AGGCCAGGCT GATGCACCAG GGACAGCTGG CCTGTGGCGG  
 101 AGCCCTGGTG TCAGAGGAGG CGGTGCTAAC TGCTGCCAC TGCTTCATTG  
 151 G

25

**SEQ ID NO: 14 (INTP039 polypeptide sequence exon 7)**

1 CGSLRTAGPQ AGAPSPWPWE ARLMHQGQLA CGGALVSEEA VLTAAHCFIG

**SEQ ID NO: 15 (INTP039 nucleotide sequence exon 8)**

30 1 GCGCCAGGCC CCAGAGGAAT GGAGCGTAGG GCTGGGGACC AGACCGGAGG  
 51 AGTGGGGCCT GAAGCAGCTC ATCCTGCATG GAGCCTACAC CCACCCCTGAG  
 101 GGGGGCTACG ACATGGCCCT CCTGCTGCTG GCCCAGCCTG TGACACTGGG  
 151 AGCCAGCCTG CGGCCCTCT GCCTGCCCTA TCCTGACCAC CACCTGCCTG  
 201 ATGGGGAGCG TGGCTGGTT CTGGGACGGG CCCGCCAGG AGCAG

35

**SEQ ID NO: 16 (INTP039 polypeptide sequence exon 8)**

1 RQAPEEWSVG LGTRPEEWGL KQLILHGAYT HPEGGYDMAL LLLAQPVTLG  
 51 ASLRPLCLPY PDHHLPDGER GWVLGRARPG AG

**SEQ ID NO: 17 (INTP039 nucleotide sequence exon 9)**

1 GCATCAGCTC CCTCCAGACA GTGCCCGTGA CCCTCCTGGG GCCTAGGGCC  
 51 TGCAGCCGGC TGCATGCAGC TCCTGGGGGT GATGGCAGCC CTATTCTGCC  
 5 101 GGGGATGGTG TGTACCAGTG CTGTGGGTGA GCTGCCAGC TGTGAG

**SEQ ID NO: 18 (INTP039 polypeptide sequence exon 9)**

1 ISSLQTVPVT LLGPRACSRL HAAPGGDGSP ILPGMVCTSA VGELPSCE

**10 SEQ ID NO: 19 (INTP039 nucleotide sequence exon 10)**

1 GGCCTGTCTG GGGCACCACT GGTGCATGAG GTGAGGGGCA CATGGTTCCCT  
 51 GGCCGGGCTG CACAGCTTCG GAGATGCTTG CCAAGGCCCC GCCAGGCCGG  
 101 CGGTCTTCAC CGCGCTCCCT GCCTATGAGG ACTGGGTCAAG CAGTTTGGAC  
 151 TGGCAGGTCT ACTTCGCCGA GGAACCAGAG CCCGAGGCTG AGCCTGGAAG  
 15 201 CTGCCTGGCC AACATAAGTA TGTGGCCCCG GGGCCTCCTG CCAAACCCCTG  
 251 CCTCTCCAGG ACCCTTCTCT CTCCAG

**SEQ ID NO: 20 (INTP039 polypeptide sequence exon 10)**

1 GLSGAPLVHE VRGTWFLAGL HSFGDACQGP ARPAVFTALP AYEDWVSSL  
 20 51 WQVYFAEEPE PEAEPGSCLA NISMWPRGLL PNPASPGPFS LQ

**SEQ ID NO: 21 (INTP039 nucleotide sequence)**

1 ATGAAGTGGT GCTGGGGCCC AGTGCTGCTC ATCGCGGGTG CCACAGTCCT  
 51 CATGGAGGGT CTTCAAGCCG CTCAGCGTGC CTGTGGACAG CGTGGCCCTGG  
 25 101 GCCCCCCCCAA GCCTCAGGAG GGCAACACAG TCCCTGGCGA GTGGCCCTGG  
 151 CAGGCCAGTG TGAGGAGGCA AGGAGCCCAC ATCTGCAGCG GCTCCCTGGT  
 201 GGCAGACACC TGGGTCCCTCA CTGCTGCCA CTGCTTGAA AAGGCAGCAG  
 251 CAACAGAACT GAATTCCCTGG TCAGTGGTCC TGGGTTCTCT GCAGCGTGAG  
 301 GGACTCAGCC CTGGGGCCGA AGAGGTGGGG GTGGCTGCC TGCAAGTTGCC  
 30 351 CAGGGCCTAT AACCAACTACA GCCAGGGCTC AGACCTGGCC CTGCTGCAGC  
 401 TCGCCCACCC CACGACCCAC ACACCCCTCT GCCTGCCCA GCCCCCCCAC  
 451 CGCTTCCCT TTGGAGCCTC CTGCTGGGCC ACTGGCTGGG ATCAGGACAC  
 501 CAGTGATGCT CCTGGGACCC TACGCAATCT GCGCCTGCGT CTCATCAGTC  
 551 GCCCCACATG TAACTGTATC TACAACCAGC TGCACCAGCG ACACCTGTCC  
 35 601 AACCCGGCCC GGCGCTGGGAT GCTATGTGGG GGCCCCCAGC CTGGGGTGCA  
 651 GGGCCCTGT CAGGGAGATT CCGGGGGCCC TGTGCTGTGC CTCGAGCCTG  
 701 ACGGACACTG GGTTCAAGGCT GGCATCATCA GCTTTGCATC AAGCTGTGCC  
 751 CAGGAGGACG CTCCCTGTGCT GCTGACCAAC ACAGCTGCTC ACAGTTCCCTG  
 801 GCTGCAGGCT CGAGTTCAAGG GGGCAGCTTT CCTGGCCAG AGCCCAGAGA

851 CCCCCGGAGAT GAGTGATGAG GACAGCTGTG TAGCCTGTGG ATCCTTGAGG  
 901 ACAGGCAGGTC CCCAGGCAGG AGCACCCCTCC CCATGGCCCT GGGAGGCCAG  
 951 GCTGATGCAC CAGGGACAGC TGGCCTGTGG CGGAGCCCTG GTGTCAGAGG  
 1001 AGGCAGGTGCT AACTGCTGCC CACTGCTTCA TTGGGCGCCA GGCCCCAGAG  
 5 1051 GAATGGAGCG TAGGGCTGGG GACCAGACCG GAGGAGTGGG GCCTGAAGCA  
 1101 GCTCATCCTG CATGGAGCCT ACACCCACCC TGAGGGGGGC TACGACATGG  
 1151 CCCTCCTGCT GCTGGCCAG CCTGTGACAC TGGGAGCCAG CCTGCAGCCC  
 1201 CTCTGCCTGC CCTATCCTGA CCACCACTG CCTGATGGGG AGCGTGGCTG  
 1251 GGTTCTGGGA CGGGCCCGCC CAGGAGCAGG CATCAGCTCC CTCCAGACAG  
 10 1301 TGCCCGTGAC CCTCCTGGGG CCTAGGGCCT GCAGCCGGCT GCATGCAGCT  
 1351 CCTGGGGGTG ATGGCAGCCC TATTCTGCG GGGATGGTGT GTACCAAGTGC  
 1401 TGTGGGTGAG CTGCCAGCT GTGAGGGCCT GTCTGGGGCA CCACTGGTGC  
 1451 ATGAGGTGAG GGGCACATGG TTCCTGGCCG GGCTGCACAG CTTGGAGAT  
 1501 GCTTGCCAAG GCCCCGCCAG GCCGGCGGTC TTCACCGCCG TCCCTGCCTA  
 15 1551 TGAGGACTGG GTCAGCAGTT TGGACTGGCA GGTCTACTTC GCCGAGGAAC  
 1601 CAGAGCCCGA GGCTGAGCCT GGAAGCTGCC TGGCCAACAT AAGTATGTGG  
 1651 CCCCGGGGCC TCCTGCCAAA CCCTGCCTCT CCAGGACCCCT TCTCTCTCCA  
 1701 G

**20 SEQ ID NO: 22 (INTP039 polypeptide sequence)**

1 MKWCWGPVILL IAGATVLMEG LQAAQRACGQ RGPGPPKPQE GNTVPGEWPW  
 51 QASVRRQGAH ICSGSLVADT WVLTAAHCFE KAAATELNSW SVVLGSLQRE  
 101 GLSPGAEEVG VAALQLPRAY NHYSQGSDLA LLQLAHPTTH TPLCLPQPAH  
 151 RFPFGASCWA TGWDQDTSDA PGTLRNLRLR LISRPCNCI YNQLHQRHLS  
 20 201 NPARPGMLCG GPQPGVQGPC QGDGGPVLC LEVDGHWVQA GIISFASSCA  
 251 QEDAPVLLTN TAAHSSWLQA RVQGAFLAQ SPETPEMSDE DSCVACGSLR  
 301 TAGPQAGAPS PWPWEARLMH QGQLACGGAL VSEEAVLAA HCFIGRQAPE  
 351 EWSVGLGTRP EEWGLKQLIL HGAYTHPEGG YDMALLLLAQ PVTLGASLRP  
 401 LCLPYPDHHL PDGERGWVLG RARPGAGISS LQTVPVTLLG PRACSRHAA  
 30 451 PGGDGSPILP GMVCTSAVGE LPSCEGLSGA PLVHEVRGTW FLAGLHSFGD  
 501 ACQGPAPAV FTALPAYEDW VSSLDWQVYF AEEPEPEAEP GSCLANISMW  
 551 PRGLLPNPAS PGPFSLO

**SEQ ID NO: 23 (INTP039 exon 2 mature nucleotide sequence)**

35 1 GCTCAGCGTG

**SEQ ID NO: 24 (INTP039 exon 2 mature polypeptide sequence)**

1 AQRA

**SEQ ID NO: 25 (INTP039 mature nucleotide sequence)**

1 GCTCAGCGTG CCTGTGGACA GCGTGGCCCC GGCCCCCCCCA AGCCTCAGGA  
 51 GGGCAACACA GTCCCTGGCG AGTGGCCCTG GCAGGCCAGT GTGAGGAGGC  
 101 AAGGAGGCCA CATCTGCAGC GGCTCCCTGG TGGCAGACAC CTGGGTCC  
 5 151 ACTGCTGCC ACTGCTTTGA AAAGGCAGCA GCAACAGAAC TGAATTCTG  
 201 GTCAGTGGTC CTGGGTTCTC TGCAGCGTGA GGGACTCAGC CCTGGGGCCG  
 251 AAGAGGTGGG GGTGGCTGCC CTGCAGTTGC CCAGGGCCTA TAACCACTAC  
 301 AGCCAGGGCT CAGACCTGGC CCTGCTGCAG CTCGCCACC CCACGACCCA  
 351 CACACCCCTC TGCCCTGCC AGCCCGCCCA TCGTTCCCC TTTGGAGCCT  
 10 401 CCTGCTGGC CACTGGCTGG GATCAGGACA CCAGTGATGC TCCTGGGACC  
 451 CTACGCAATC TGCCGCTGCC TCTCATCAGT CGCCCCACAT GTAACTGTAT  
 501 CTACAACCAG CTGCACCAGC GACACCTGTC CAACCCGGCC CGGCCTGGGA  
 551 TGCTATGTGG GGGCCCCCAG CCTGGGGTGC AGGGCCCCTG TCAGGGAGAT  
 601 TCCGGGGGCC CTGTGCTGTG CCTCGAGCCT GACGGACACT GGGTTCAAGGC  
 15 651 TGGCATCATC AGCTTTGCAT CAAGCTGTGC CCAGGAGGAC GCTCCTGTGC  
 701 TGCTGACCAA CACAGCTGCT CACAGTTCTT GGCTGCAGGC TCGAGTTCAG  
 751 GGGGCAGCTT TCCTGGCCCA GAGCCCAGAG ACCCCGGAGA TGAGTGATGA  
 801 GGACAGCTGT GTAGCCTGTG GATCCTTGAG GACAGCAGGT CCCCAGGCAG  
 851 GAGCACCCCTC CCCATGGCCCA TGGGAGGCCA GGCTGATGCA CCAGGGACAG  
 20 901 CTGGCCTGTG GCGGAGCCCT GGTGTCAGAG GAGGCGGTGC TAACTGCTGC  
 951 CCACTGCTTC ATTGGGCGCC AGGCCCCAGA GGAATGGAGC GTAGGGCTGG  
 1001 GGACCAGACC GGAGGAGTGG GGCCTGAAGC AGCTCATCCT GCATGGAGCC  
 1051 TACACCCACC CTGAGGGGGG CTACGACATG GCCCTCCTGC TGCTGGCCCA  
 1101 GCCTGTGACA CTGGGAGCCA GCCTGCGGCC CCTCTGCCCTG CCCTATCCTG  
 25 1151 ACCACCACCT GCCTGATGGG GAGCGTGGCT GGGTTCTGGG ACGGGCCCC  
 1201 CCAAGGAGCAG GCATCAGCTC CCTCCAGACA GTGCCCGTGA CCCCTCTGGG  
 1251 GCCTAGGGCC TGCAGCCGGC TGCATGCAGC TCCTGGGGGT GATGGCAGCC  
 1301 CTATTCTGCC GGGGATGGTG TGTACCAGTG CTGTGGGTGA GCTGCCAGC  
 1351 TGTGAGGGCC TGTCTGGGC ACCACTGGTG CATGAGGTGA GGGGCACATG  
 30 1401 GTTCCCTGGCC GGGCTGCACA GCTTCGGAGA TGCTTGCAA GGCCCCGCCA  
 1451 GGCCGGCGGT CTTCACCGCG CTCCCTGCCT ATGAGGACTG GGTCAGCAGT  
 1501 TTGGACTGGC AGGTCTACTT CGCCGAGGAA CCAGAGCCCG AGGCTGAGCC  
 1551 TGGAAGCTGC CTGGCCAACA TAAGTATGTG GCCCCGGGGC CTCCCTGCCAA  
 1601 ACCCTGCCTC TCCAGGACCC TTCTCTCTCC AG

35

**SEQ ID NO: 26 (INTP039 mature polypeptide sequence)**

1 AQRACQQRGP GPPKPQEGLNT VPGEWPWQAS VRROGAHICS GSLVADTWVL  
 51 TAAHCFEKAA ATELNSWSVV LGSLQREGLS PGAEEVGVAA LQLPRAYNHY  
 101 SQGSDLALLQ LAHPTTHPL CLPQPAHREF FGASCWATGW DQDTSDAPGT  
 40 151 LRNLRLRLIS RPTCNCIYNQ LHQRHLSNPA RPGMLCGGPQ PGVQGPCQGD

201 SGGPVLCLEP DGHWVQAGII SFASSCAQED APVLLTNTAA HSSWLQARVQ  
251 GAAFLAQSPPE TPEMSDEDSC VACGSLRTAG PQAGAPSPWP WEARLMHQGQ  
301 LACGGALVSE EAVLTAAHCF IGRQAPEEWS VGLGTRPEEW GLKQLILHGA  
351 YTHPEGGYDM ALLLLAQPVT LGASLRPLCL PYPDHHLPDG ERGWVLGRAR  
5 401 PGAGISSLQT VPVTLLGPRA CSRLHAAPGG DGSPILPGMV CTSAVGELPS  
451 CEGLSGAPLV HEVRGTWFLA GLHSFGDACQ GPARPAVFTA LPAYEDWVSS  
501 LDWQVYFAEE PEPEAEPGSC LANISMWPRG LLPNPASP GP FSLQ

**CLAIMS**

1. A polypeptide, which polypeptide:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, 5 SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and/or SEQ ID NO:26;
- (ii) is a fragment thereof which functions as a serine protease which is a member of the trypsin family of proteins, or having an antigenic determinant in common with the polypeptide of (i); or
- 10 (iii) is a functional equivalent of (i) or (ii).

2. A polypeptide according to claim 1 which:

- (i) comprises the amino acid sequence as recited in SEQ ID NO:22 or SEQ ID NO:26;
- (ii) is a fragment thereof which functions as a serine protease which is a member of 15 the trypsin family of proteins, or having an antigenic determinant in common with the polypeptide of (i); or
- (iii) is a functional equivalent of (i) or (ii).

3. A polypeptide according to claim 1 or 2 which:

- (i) consists of the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, 20 SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and/or SEQ ID NO:26;
- (ii) is a fragment thereof which functions as a serine protease which is a member of 25 the trypsin family of proteins, or having an antigenic determinant in common with the polypeptide of (i); or
- (iii) is a functional equivalent of (i) or (ii).

4. A polypeptide which is a functional equivalent according to part (iii) of any of the above claims, characterised in that it is homologous to the amino acid sequence as recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID

NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 or SEQ ID NO:26 and is a member of the trypsin family of proteins.

5. A polypeptide which is a fragment or a functional equivalent as recited in any one of claims 1 to 4, which has greater than 80% sequence identity with the amino acid sequence recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 or SEQ ID NO:26 or with an active fragment thereof, preferably greater than 85%, 90%, 95%, 98% or 99% sequence identity.
10. 6. A polypeptide which is a functional equivalent as recited in any one of claims 1 to 5, which exhibits significant structural homology with a polypeptide having the amino acid sequence recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 or SEQ ID NO:26.
15. 7. A polypeptide which is a fragment as recited in any one of claims 1-3 and claim 5 having an antigenic determinant in common with the polypeptide of part (i) of any one of claim 1 to claim 3 which consists of 7 or more amino acid residues from the amino acid sequence recited in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 or SEQ ID NO:26.
20. 8. A purified nucleic acid molecule which encodes a polypeptide according to any one of the preceding claims.
25. 9. A purified nucleic acid molecule according to claim 8, which comprises the nucleic acid sequence as recited in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23 and/or SEQ ID NO:25, or is a redundant equivalent or fragment thereof.
30. 10. A purified nucleic acid molecule according to claim 8 or claim 9 which consists of the nucleic acid sequence as recited in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23 and/or SEQ ID NO:25, or is a redundant equivalent or fragment thereof.

11. A purified nucleic acid molecule which hybridizes under high stringency conditions with a nucleic acid molecule according to any one of claims 8 to 10.
12. A vector comprising a nucleic acid molecule as recited in any one of claims 8 to 11.
13. A host cell transformed with a vector according to claim 12.
- 5 14. A ligand which binds specifically to the trypsin polypeptide according to any one of claims 1 to 7.
15. A ligand according to claim 14, which is an antibody.
16. A compound that either increases or decreases the level of expression or activity of a polypeptide according to any one of claims 1 to 7.
- 10 17. A compound according to claim 16 that binds to a polypeptide according to any one of claims 1 to 7 without inducing any of the biological effects of the polypeptide.
18. A compound according to claim 17, which is a natural or modified substrate, ligand, enzyme, receptor or structural or functional mimetic.
19. A polypeptide according to any one of claims 1 to 7, a nucleic acid molecule according to any one of claims 8 to 11, a vector according to claim 12, a host cell according to claim 13, a ligand according to claim 14 or claim 15, or a compound according to any one of claims 16 to 18, for use in therapy or diagnosis of disease.
- 20 20. A method of diagnosing a disease in a patient, comprising assessing the level of expression of a natural gene encoding a polypeptide according to any one of claims 1 to 7, or assessing the activity of a polypeptide according to any one of claims 1 to 7, in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease.
21. A method according to claim 20 that is carried out *in vitro*.
22. A method according to claim 20 or claim 21, which comprises the steps of: (a) contacting a ligand according to claim 14 or claim 15 with a biological sample under conditions suitable for the formation of a ligand-polypeptide complex; and (b) detecting said complex.
- 25 23. A method according to claim 20 or claim 21, comprising the steps of:
  - a) contacting a sample of tissue from the patient with a nucleic acid probe under

stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of claims 8 to 11 and the probe;

b) contacting a control sample with said probe under the same conditions used in step a); and

5 c) detecting the presence of hybrid complexes in said samples; wherein detection of levels of the hybrid complex in the patient sample that differ from levels of the hybrid complex in the control sample is indicative of disease.

24. A method according to claim 20 or claim 21, comprising:

a)contacting a sample of nucleic acid from tissue of the patient with a nucleic acid 10 primer under stringent conditions that allow the formation of a hybrid complex between a nucleic acid molecule according to any one of claims 8 to 11 and the primer;

b)contacting a control sample with said primer under the same conditions used in step a); and

c)amplifying the sampled nucleic acid; and

15 d)detecting the level of amplified nucleic acid from both patient and control samples; wherein detection of levels of the amplified nucleic acid in the patient sample that differ significantly from levels of the amplified nucleic acid in the control sample is indicative of disease.

25. A method according to claim 20 or claim 21 comprising:

20 a)obtaining a tissue sample from a patient being tested for disease;

b)isolating a nucleic acid molecule according to any one of claims 8 to 11 from said tissue sample; and

c)diagnosing the patient for disease by detecting the presence of a mutation which is associated with disease in the nucleic acid molecule as an indication of the disease.

25 26. The method of claim 25, further comprising amplifying the nucleic acid molecule to form an amplified product and detecting the presence or absence of a mutation in the amplified product.

27. The method of claim 25 or claim 26, wherein the presence or absence of the mutation in the patient is detected by contacting said nucleic acid molecule with a nucleic acid

probe that hybridises to said nucleic acid molecule under stringent conditions to form a hybrid double-stranded molecule, the hybrid double-stranded molecule having an unhybridised portion of the nucleic acid probe strand at any portion corresponding to a mutation associated with disease; and detecting the presence or absence of an unhybridised portion of the probe strand as an indication of the presence or absence of a disease-associated mutation.

- 5                    28. A method according to any one of claims 20 to 27, wherein said disease includes, but is not limited to, cell proliferative disorders and/or differentiative disorders, such as carcinoma, sarcoma, solid tumours including prostate, breast, lung, testis, ovary, head and neck, brain or bone tumour, metastatic disorders or hematopoietic neoplastic disorders; disorders of bone metabolism, such as osteoporosis, osteodystrophy, osteomalacia, rickets, osteitis fibrosa cystica, renal osteodystrophy, osteosclerosis, osteopenia, fibrogenesis-imperfecta ossium, secondary hyperparathyroidism, hypoparathyroidism, hyperparathyroidism; periodontal disease, immune/autoimmune disorders such as, arthritis, multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus erythematosus, autoimmune thyroiditis, dermatitis, psoriasis; Sjogren's Syndrome, Crohn's disease, ulcer, iritis, conjunctivitis, ulcerative colitis, asthma; scleroderma, autoimmune uveitis, allergic encephalomyelitis, hearing loss, aplastic anemia, anemia, idiopathic thrombocytopenia, polychondritis, Graves' disease, graft-versus-host disease, allergy; hematopoietic disorders; cardiovascular disorders such as hypertension, atherosclerosis, congestive heart failure, coronary artery disease, arrhythmias, cardiomyopathies, atherosclerosis, hypertensive vascular disease, Raynaud disease, aneurysms, varicose veins, thrombophlebitis, phlebothrombosis, tumors, hemangioma, lymphangioma, glomus tumor (glomangioma), Kaposi sarcoma, angiosarcoma, hemangiofibroma; blood clotting disorders, such as hemorrhagic diatheses, nonthrombocytopenic purpura, thrombocytopenia, idiopathic thrombocytopenic purpura, HIV-associated thrombocytopenia, thrombotic microangiopathies, hemorrhagic diatheses, lymphomas, Hodgkin disease; liver disorders such as, cirrhosis, hepatocellular necrosis, liver fibrosis, Al-antitrypsin deficiency, hemochromatosis copper storage diseases and liver damage (especially drug or alcohol induced); bacterial, fungal or viral infection; pain or metabolic disorders, such as obesity, anorexia nervosa, cachexia, lipid disorders, and diabetes; AIDS and other pathological conditions in which serine proteases of the trypsin family

are implicated.

29. A method according to any one of claims 20 to 27, wherein said disease is a disease in which trypsin proteins are implicated.
30. Use of a polypeptide according to any one of claims 1 to 7 as a serine protease which is  
5 a member of the trypsin family of proteins.
31. A pharmaceutical composition comprising a polypeptide according to any one of claims 1 to 7, a nucleic acid molecule according to any one of claims 8 to 11, a vector according to claim 12, a host cell according to claim 13, a ligand according to claim 14 or claim 15, or a compound according to any one of claims 16 to 18.
- 10 32. A vaccine composition comprising a polypeptide according to any one of claims 1 to 7 or a nucleic acid molecule according to any one of claims 8 to 11.
33. A polypeptide according to any one of claims 1 to 7, a nucleic acid molecule according to any one of claims 8 to 11, a vector according to claim 12, a host cell according to claim 13, a ligand according to claim 14 or claim 15, a compound according to any one of claims 16 to 18, or a pharmaceutical composition according to claim 31, for use in  
15 the manufacture of a medicament for the treatment of cell proliferative disorders and/or differentiative disorders, such as carcinoma, sarcoma, solid tumours including prostate, breast, lung, testis, ovary, head and neck, brain or bone tumour, metastatic disorders or hematopoietic neoplastic disorders; disorders of bone metabolism, such as osteoporosis, osteodystrophy, osteomalacia, rickets, osteitis fibrosa cystica, renal osteodystrophy, osteosclerosis, osteopenia, fibrogenesis-imperfecta ossium, secondary hyperparathyroidism, hypoparathyroidism, hyperparathyroidism; periodontal disease, immune/autoimmune disorders such as, arthritis, multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus erythematosus, autoimmune thyroiditis, dermatitis,  
20 psoriasis, Sjogren's Syndrome, Crohn's disease, ulcer, iritis, conjunctivitis, ulcerative colitis, asthma, scleroderma, autoimmune uveitis, allergic encephalomyelitis, hearing loss, aplastic anemia, anemia, idiopathic thrombocytopenia, polychondritis, Graves' disease, graft-versus-host disease, allergy; hematopoietic disorders; cardiovascular disorders such as hypertension, atherosclerosis, congestive heart failure, coronary  
25 artery disease, arrhythmias, cardiomyopathies, arteriosclerosis, hypertensive vascular disease, Raynaud disease, aneurysms, varicose veins, thrombophlebitis, phlebothrombosis, tumors, hemangioma, lymphangioma, glomus tumor

(glomangioma), Kaposi sarcoma, angiosarcoma, hemangiopericytoma; blood clotting disorders, such as hemorrhagic diatheses, nonthrombocytopenic purpuras, thrombocytopenia, idiopathic thrombocytopenic purpura, HIV-associated thrombocytopenia, thrombotic microangiopathies, hemorrhagic diatheses, lymphomas, Hodgkin disease; liver disorders such as, cirrhosis, hepatocellular necrosis, liver fibrosis, Al-antitrypsin deficiency, hemochromatosis copper storage diseases and liver damage (especially drug or alcohol induced); bacterial, fungal or viral infection; pain or metabolic disorders, such as obesity, anorexia nervosa, cachexia, lipid disorders, and diabetes; AIDS and other pathological conditions.

- 10 34. A polypeptide according to any one of claims 1 to 7, a nucleic acid molecule according to any one of claims 8 to 11, a vector according to claim 12, a host cell according to claim 13, a ligand according to claim 14 or claim 15, a compound according to any one of claims 16 to 18, or a pharmaceutical composition according to claim 31, for use in the manufacture of a medicament for the treatment of a disease in which the trypsin family of proteins are implicated.
- 15 35. A method of treating a disease in a patient, comprising administering to the patient a polypeptide according to any one of claims 1 to 7, a nucleic acid molecule according to any one of claims 8 to 11, a vector according to claim 12, a host cell according to claim 13, a ligand according to claim 14 or claim 15, a compound according to any one of claims 16 to 18, or a pharmaceutical composition according to claim 31.
- 20 36. A method according to claim 35, wherein, for diseases in which the expression of the natural gene or the activity of the polypeptide is lower in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, ligand, compound or composition administered to the patient is an agonist.
- 25 37. A method according to claim 35, wherein, for diseases in which the expression of the natural gene or activity of the polypeptide is higher in a diseased patient when compared to the level of expression or activity in a healthy patient, the polypeptide, nucleic acid molecule, vector, ligand, compound or composition administered to the patient is an antagonist.
- 30 38. A method of monitoring the therapeutic treatment of disease in a patient, comprising monitoring over a period of time the level of expression or activity of a polypeptide

according to any one of claims 1 to 7, or the level of expression of a nucleic acid molecule according to any one of claims 8 to 11 in tissue from said patient, wherein altering said level of expression or activity over the period of time towards a control level is indicative of regression of said disease.

- 5 39. A method for the identification of a compound that is effective in the treatment and/or diagnosis of disease, comprising contacting a polypeptide according to any one of claims 1 to 7, or a nucleic acid molecule according to any one of claims 8 to 11 with one or more compounds suspected of possessing binding affinity for said polypeptide or nucleic acid molecule, and selecting a compound that binds specifically to said  
10 nucleic acid molecule or polypeptide.
40. A kit useful for diagnosing disease comprising a first container containing a nucleic acid probe that hybridises under stringent conditions with a nucleic acid molecule according to any one of claims 8 to 11; a second container containing primers useful for amplifying said nucleic acid molecule; and instructions for using the probe and  
15 primers for facilitating the diagnosis of disease.
41. The kit of claim 40, further comprising a third container holding an agent for digesting unhybridised RNA.
42. A kit comprising an array of nucleic acid molecules, at least one of which is a nucleic acid molecule according to any one of claims 8 to 11.
- 20 43. A kit comprising one or more antibodies that bind to a polypeptide as recited in any one of claims 1 to 7; and a reagent useful for the detection of a binding reaction between said antibody and said polypeptide.
44. A transgenic or knockout non-human animal that has been transformed to express higher, lower or absent levels of a polypeptide according to any one of claims 1 to 7.
- 25 45. A method for screening for a compound effective to treat disease, by contacting a non-human transgenic animal according to claim 44 with a candidate compound and determining the effect of the compound on the disease of the animal.
46. A polypeptide according to any one of claims 1 to 7, a nucleic acid molecule according to any one of claims 8 to 11, a vector according to claim 12, a host cell according to claim 13, a ligand according to claim 14 or claim 15, a compound according to any one of claims 16 to 18, or a pharmaceutical composition according to claim 31 for use in

IVF or as a contraceptive.

47. A polypeptide according to any one of claims 1 to 7, a nucleic acid molecule according to any one of claims 8 to 11, a vector according to claim 12, a host cell according to claim 13, a ligand according to claim 14 or claim 15, a compound according to any one of claims 16 to 18, or a pharmaceutical composition according to claim 31 for use in the manufacture of a contraceptive.

**Figure 1: Top 10 BLASTP results for INTP039 against NCBI non-redundant database.**

		Score (bits)	E Value
gb AAH39632.1	Similar to protease, serine, 8 (prostasin) [Mus musculus]	714	0.0
dbj BAC11431.1	Unnamed protein product [Homo sapiens]	266	6e-70
ref XP_110113.1	RIKEN cDNA 1300008A22 [Mus musculus]	173	7e-42
ref NP_114154.1	Marapsin; channel-activating protease 2 [Homo sapiens]	172	9e-42
gb AAH36846.1	Similar to protease, serine, 8 (Prostasin) [Homo sapiens]	172	1e-41
ref NP_690851.1	Serine protease EOS [Homo sapiens]	172	2e-41
emb CAC85953.1	Matriptase-2 [Homo sapiens]	167	3e-40
ref NP_705837.1	Type II transmembrane serine protease 6 [Homo sapiens]	167	3e-40
ref XP_128466.1	Similar to RIKEN cDNA [Mus musculus]	165	2e-39
gb AAG32641.1	Prostasin [Rattus norvegicus]	165	2e-39

**Figure 2: Alignment between INTP039 polypeptide sequence (SEQ ID NO:22) and the hit, NP\_114154.1.**

ref|NP\_114154.1| marapsin; channel-activating protease 2 [Homo sapiens]  
sp|Q9BQR3|MPN\_HUMAN Marapsin precursor  
emb|CAC35467.1| marapsin [Homo sapiens]  
gb|AAK38168.1| pancreasin [Homo sapiens]  
Length = 290

Score = 172 bits (437), Expect = 9e-42  
Identities = 88/236 (37%), Positives = 132/236 (55%), Gaps = 12/236 (5%)

Query: 42 NTVPGEPWQASVRRQGAHICSGSLVADT WVL TAAHC F EKA AATE LNSWS VVL G S L Q REG 101  
+ T GEWP WQ S++R G+H C GSL+A+ WVL TAAHC F + T L + V+LG+ Q  
Sbjct: 40 DTQE GEWP WQVSIQRNGSHFCGGSLIAEQW VL TAAHC FRNT SETSL--YQVLLGARQLVQ 97

Query: 102 LSPGAEEVGVAALQLP RAYNHYSQGS DL ALLQLA HPTTHT----PLCLP QPAH RFP F G AS 157  
P A V ++ Y + +D+AL++L P T P+CLP P+ F G +  
Sbjct: 98 PGPHAMYARVRQVESN PLYQGTASSADVALVELEAPVPFTNYILPVCLPDPSVIFETGMN 157

Query: 158 CWATGW----DQDTSDAPGTLRNRLRLISRPTCNCIYNQ-LHQRHLSNP ARPGMLCCGP 212  
CW TGW ++D P L+ L + I P CN +Y++ + + MLC G  
Sbjct: 158 CWVTG WGSPSEEDLLPEPRILQKLAVPIIDTPKCNLLYSKDTEFGYQPKTIKNDMLCAGF 217

Query: 213 QPGVQGPCQGDGGPVLCLEPDGHWVQAGIIISFASSCAQEDAPVLLNTAAHSSWL 268  
+ G + C+GDSGGP++CL W+QAG+IS+ CA+++ P+ AH +W+  
Sbjct: 218 EEGKKDACKGDGGPLVCLVGQS-WLQAGVISWGEGCARQNRPGVYIRVTAAHHNWI 272

Score = 104 bits (259), Expect = 4e-21  
Identities = 75/251 (29%), Positives = 110/251 (42%), Gaps = 21/251 (8%)

Query: 292 SCVACGSLRT----AGPQAGAPSPWPWEARLMHQQLACGGALVSEEAVL TAAHC FIGRQ 347  
+ ACG R G Q WPW+ + G CGG+L++E+ VLTAAHCF  
Sbjct: 22 AATACGRPRMLNRMVGGQDTQE GEWP WQVSIQRNGSHFCGGSLIAEQW VL TAAHC FRNTS 81

Query: 348 APEEWSVGLGTR-----PEEW--GLKQLL LH GAYTHPEGGYDMALLLAQP VTL GASLR 399  
+ V LG R P ++Q+ + Y D+AL+ L PV . +  
Sbjct: 82 ETSLYQVLLGARQLVQPGPHAMYARVRQVESN PLYQGTASSADVALVELEAPVPFTNYIL 141


Query: 400 PLCLPYPDHHL PDGERGWVLGRARPG----AGISSLQTVPVTLLGPRACSR LHAAP--- 451  
P+CLP P G WV G P LQ + V ++ C+ L++  
Sbjct: 142 PVCLPDPSVIFETGMNCWVTG WGSPSEEDLLPEPRILQKLAVPIIDTPKCNLLYSKDTEF 201

Query: 452 GGDGSPILPGMVCTS-AVGELPSCEGLSGAPLVHEVR GTWFLAGLHSFGDACQGPRAV 510  
G I M+C G+ +C+G SG PLV V +W AG+ S+G+ C RP V  
Sbjct: 202 GYQPKTIKNDMLCAGFEEGK DACKGDGGPLVCLVGQS WLQAGVISWGEGCARQNRPGV 261

Query: 511 FTALPAYEDWV 521  
+ + A+ +W+  
Sbjct: 262 YIRVTAAHHNWI 272

**Figure 3: SigP cleavage site prediction for INTP039.**


**SignalP-NN result:**



```
>INTP039.pep      length = 70
# Measure  Position  Value  Cutoff  signal peptide?
max. C    24       0.306   0.33   NO
max. Y    24       0.447   0.32   YES
max. S    11       0.990   0.82   YES
mean S   1-23     0.820   0.47   YES
# Most likely cleavage site between pos. 23 and 24: LQA-AQ
```

**SignalP-HMM**


**result:**




```
>INTP039.pep
Prediction: Signal peptide
Signal peptide probability: 0.998
Signal anchor probability: 0.000
Max cleavage site probability: 0.444 between pos. 23 and 24
```



**Figure 4: INTP039 domain organisation**

INTP039 of signal peptide followed by two Trypsin domains.




**Figure 5: INTP039 multiple alignment**






**Figure 6: Model of INTP039 domains 1 and 2**

Domain 1 (ribbon) : Template 1BUI (strand) Human Microplasmin 34% ID




Domain 2 (ribbon) : Template 1EAX (strand) Human Matriptase 33% ID



PCT Application

**GB0305404**



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS
- IMAGE CUT OFF AT TOP; BOTTOM OR SIDES
- FADED TEXT OR DRAWING
- BLURRED OR ILLEGIBLE TEXT OR DRAWING
- SKEWED/SLANTED IMAGES
- COLOR OR BLACK AND WHITE PHOTOGRAPHS
- GRAY SCALE DOCUMENTS
- LINES OR MARKS ON ORIGINAL DOCUMENT
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.